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ZUSAMMENFASSUNG 
Die Parkinsonsche Erkrankung (PD) ist eine chronisch, progressiv verlaufende, 
neurodegenerative Krankheit, die vor allem bei älteren Menschen vorkommt. Dabei 
kommt es in vielen Hirnregionen, vor allem aber in der Pars compacta der Substantia 
nigra, zum Absterben von dopaminergen Neuronen. Zu den damit verbundenen 
klinischen Symptomen zählt verlangsamte Bewegung, Muskelzittern, 
Haltungsinstabilität und Muskel steifheit. Obwohl die Ursache für die Erkrankung noch 
unbekannt i st, wurden einige Faktoren entdeckt, die für den Ausbruch und Fortschritt 
der Erkrankung verantwortlich sind. Zu Diesen zählen synaptische Proteine, 
Chaperone sowie Kinasen, welche im mutierten oder amplifizierten Zustand zu 
frühzeitigen Ausbruch der Krankheit führen. LRRK2, eine Leucine-rich repeat Kinase, 
ist bei den meisten familiären PD Fällen mutiert. Deshalb scheint das LRRK2 Gen 
eine wesentliche Rolle bei der Entstehung der Krankheit zu spielen. Derzeit existiert 
nur ein hLRRK2 Tiermodell, das die wichtigsten Aspekte von PD aufzeigt, allerdings 
mit  einer Mutation die nur in wenigen PD Fällen auftritt. Um die genauen Effekte von 
LRRK2 und dessen Rolle in PD zu studieren, wurde eine wildtyp-hLRRK2 Mauslinie 
entwickelt und char akterisiert.  
hLRRK2 cDNA wurde erfolgreich in einen neuronenspezifischen Expressionsvektor 
kloniert, was durch Sequenzierung, verschiedene Restriktionsverdaue und 
Expressionsanalyse in eukaryotischen Zellen bestätigt wurde. Unter dem starken 
CMV Promoter konnte das Protein bei ca. 280 kD detektiert werden, wodurch die 
Funktionalität des cDNA Konstrukts bestätigt wurde. Der neuronenspezifi sche, 
schwächere Thy1.2 Promoter induziert ebenfalls die vollständige Expression von 
hLRRK2. Vier Founder Linien mit jeweils 1, 6, 20 und 60 Kopien des Transgens 
wurden charakterisiert. qPCR mit RNA aus Hirngewebe zeigte eine leichte 
Überexpression der hLRRK2-RNA, das Protein konnte aber weder durch WB noch 
IHC in den vier Monate alten Tieren nachgewiesen werden. Eine anfängliche 
Charakterisierung mittels Pole, Beam und Grip-Test konnte bei den transgenen 
Mäusen keine motorischen Defekte feststellen, was wahrscheinlich auf die niedrige 
Expression des Konst rukts in den jungen Tieren zurückzuführen ist.  
Zusammenfassend zeigen unsere Ergebnisse, daß die Expression von LRRK2 unter 
dem neuronenspezifischen Thy1.2 Promoter lebensfähige Nachkommen 
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hervorbringt. Diese Tiere können, wenn sie PD typische Symptome im höheren Alter 
aufzeigen, als Modell für die Erkrankung verwendet werden. Dieses neuartige 
Tiermodell wäre einerseits geeignet, Funktion und Rolle von LRRK2 im Verlauf von 
PD zu studieren, andererseits könnte es zur Entwicklung und Testung neuartiger 
Medikamente und Behandl ungsmethoden verwendet wer den.  
  7 
SUMMARY 
Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder 
primarily found in elderly people. Neuronal loss of dopaminergic neurons in the brain, 
especial ly the pars compacta of the substantia nigra, leads to clinical symptoms such 
as slowing of movements, resting tremor, postural instability and rigidity. Although the 
cause of the disease is still unknown several factors were recently identified, which 
correlate with onset and progression of the disease. Such factors include synaptic 
proteins, chaperones as well as kinases, which were shown to lead to early onset of 
the disease when amplified or mutated. LRRK2 a leucine-rich repeat kinase is the 
protein most frequently found to be mutated in familial forms of PD. Therefore the 
LRRK2 gene seems to play an essential role in the onset of the disease. At present 
there is only one animal model for LRRK2 described, which mimics some aspects of 
the disease, but harbours a mutation which is found only in a minor percentage of all 
PD cases. To study the effect of LRRK2 and its role in PD a mouse model transgenic 
for the human LRRK2 pr otein was generated and initially characterized.  
hLRRK2 cDNA constructs were successfully cloned into a neuron specific 
mammalian expression vector, which was verified by restriction digest, sequencing 
and expression analysis in eukaryotic cells. Under the strong CMV promoter, protein 
was detectable at around 280 kD, indicating functionali ty of the cDNA construct. The 
neuron specific weaker Thy1.2 promoter also induced expression of hLRRK2 in CHO 
or HEK cells. Four founder lines were characterised harbouring 1, 6, 20 and 60 
copies of the transgene. Although qPCR from brain derived RNA resulted in 
moderate over-expression of the hLRRK2 RNA, hardly any LRRK2 protein was 
detectable in WB or IHC in 4 month old animals. An initial motor characterization of 
the mice failed to show detectable defects as tested by pole, beam or grip-test, 
probably due to the low expression of the construct in these young mi ce.  
Taken together our results show that expression of LRRK2 under the neuron specific 
Thy1.2 promoter results in viable offspring, which might be a useful model for PD, 
when showing PD like symptoms at older age. Such a model should be highly 
valuable to obtain deeper insight into the role of LRRK2 in PD and will serve as a 
new tool for drug evaluation and devel opment.  
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ABBREVIATIONS 
aa  amino acid 
AB  antibody 
Ampr  ampicillin resistance 
ANK  ankyrin domain 
APS  ammonium persulfate 
BAC  bacterial artificial chromosome 
biot.  Biotinylated 
bp  base pair 
BSA  bovine serum albumin 
cDNA  complementary DNA 
CDS  coding sequence 
CHO  Chinese hamster  ovary cells 
CMV  cytomegalovirus 
CNS  central nervous system 
COMT catechol-O-methyl transferase 
COR  C-terminus of ROC domai n 
C-terminus carboxy terminus  
DAB  3,3´-diaminobenzidine 
DAPI  4´,6-diamidino-2-phenylindole 
DEPC  diethylpyrocarbonate 
DH5 α  competent cell s 
diff.  differentiated 
DMEM Dulbecco´s modified eagle medium  
DMSO dimethylsulfoxid  
DNA  deoxyribonucleic acid 
DNase deoxyribonuclease  
dNTP  deoxynucleoside triphosphate 
dsDNA double strand deoxyr ibonucleic acid  
DTT  dithiothreitol 
ECL  enhanced chemi luminescence 
EDTA  ethylene diamine tetraacedic acid 
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FCS  foetal calf serum 
FICC  fluorescence immunocytochemi stry 
Fig.  figure 
fw  forward 
GAPDH glyceraldehyde-3-phosphatdehydr ogenase  
gDNA  genomic deoxyribonucleic acid 
GFP  green fluorescent protein 
h  human 
HEK  Human embryonic kidney cell s 
HRP  horse radish peroxidase 
Hz  hertz 
ICC  immunocytochemistry 
IHC  immunohistochemistry 
IL  interleukine 
IMDM  Iscove´s modified Dulbecco´s medium 
kb  kilo base pairs 
kD  kilo Dalton 
LB  lysogeny broth  
L-dopa Levodopa,  L-3,4-dihydroxyphenylalanine  
LRR  leucine-rich repeat domain 
LRRK2 Leucine-rich repeat kinase 2  
m  mouse 
MAO-B monoamine oxidase B  
MAPKKK mitogen-activated protein kinase kinase kinase domain  
MCS  multi cloning site 
mRNA messenger ribonucleic acid 
NaOV  sodium ortho vanadate  
NEAA  non-essential amino acid 
neg.  negative 
N-terminus amino-terminus  
NTP  nucleotide triphosphate 
OD  optical density 
Oligo dT poly deoxythymidine  
ORF  open reading frame 
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PBS  phosphate buffer ed saline 
PBST  phosphate buffer ed saline tween 
PCR  polymerase chain reaction 
PD  Parkinson’s disease 
PFA  paraformaldehyde 
qPCR  quantitative polymerase chain reaction 
r  rabbit 
RA  retinoic acid 
rec.  recombinant 
rev  reverse 
RIPA  radioimmunoprecipitation assay buffer  
RNA  ribonucleic acid 
RNase ribonuclease  
ROC  Ras of complex domain, GTPase 
Rpl32  ribosomal protein L32 
RT  reverse transcriptase 
RT  room temperature 
RT-PCR reverse transcriptase polymerase chain reaction  
SDS  sodiumdodecylsulphate 
SH-SY5Y neuroblastoma cells  
sp.c.  spinal cord 
sqPCR semi-quantitative PCR 
SS II RT reverse transcriptase  
stom.  Stomach 
TAE  Tris acetic acid EDTA 
tg  transgene 
TH  tyrosine hydroxylase 
Thy1.2 glycophosphatidylinositol linked surface protein  
WB  Western Blotting 
WD40  tryptophan-aspartic acid 40 dipeptide repeat 
wt  wild type 
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1 INTRODUCTION 
1.1 Parkinson’s disease 
Parkinson’s disease (PD) is named after the physician James Parkinson who first 
described the disease in 1817 in his work titled “An Essay on the Shaking Palsy” in 
which he mentioned six patients with PD symptoms [1].  
 
The disease is a chronic and progressive neurodegener ative disorder mainly 
affecting the extrapyramidal motor system. People affected by the disease show 
symptoms including slowing of movement (bradykinesia), resting tremor (4-6 Hz 
tremor, most noticeable at resting position), postural instability (loss of balance) and 
rigidity (stiffness with increased muscle tone). Secondary symptoms include cognitive 
dysfunction, depression and aphasia [2]. Symptoms are mainly caused by death of 
neurons producing the neurotransmitter dopamine in the pars compacta of the 
substantia nigra. Other regions of the brain stem including the locus coeruleus, raphe 
nuclei and others are also affected by cell  loss [3].  
 
The incidence of the disease increases with age, especially occurring with the age of 
60 and elder. Male persons have an 1,9 fold higher incidence to get PD than 
females. An exception is the Asian population where the risk to develop the disease 
is lower in men. Incidence rates concerning race/ethnicity are the highest for 
Hispanics, then Non-Hispanic Whites, Asians and lowest for Blacks [4]. In Austria ~ 
30.000 people, in Germany ~250.000 people and in America more than 1.500.000 
people (more than 60.000 new cases per year) are affected by the disease. The 
average duration from diagnosis to death is currently 15 years, with pneumonia as 
the most common cause for  demise [1].  
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1.1.1  Classification of PD 
 
There are four different subclasses of PD which are all characterized by 
bradykinesia, tremor, rigidity and postural instability which are classified as follows 
(classification is based on symptoms of the Parkinson's disease which are described 
in the EMEA Guideline on Clinical Investigation of Medicinal Products in the 
Treatment of Parkinson’s Disease (CPMP/EWP/563/95 Rev.1) ): 
· Familial Parkinson syndromes originate from mutations in different proteins 
(eg. LRRK2, al pha-synuclein, parkin and others) 
· Idiopathic Parkinson syndromes with unknown cause (~75% of PD cases) . 
· Secondary PD syndromes due to drug misuse (e.g. MPTP) or different 
diseases which cause these symptoms (e.g. vascular disease, metabolic 
disease, inflammation or after brain injury).  
· Other neurodegenerative diseases which cause Parkinsonism such as 
multiple system atrophy, progressive supranuclear palsy, corticobasal 
degeneration and dementia with lewy bodies are summarized as PD+ 
syndromes.  
 
1.1.2  Pathophysiology 
 
Parkinson symptoms are caused by decreased secretion of the neurotransmitter 
dopamine from neurons of the substant ia nigra a substructure of the mesencephalon. 
Loss of these neurons leads to an imbalance of movement regulation, by blocking 
brain regions which facilitate movement and in contrast by stimulating regions which 
inhibit movement (both in the basal ganglia). The subsequently decreased dopamine 
levels lead to inhibition of excitatory projections from the ventral anterior nucleus of 
the thalamus to the motor cortex, leading to reduced motor activity (Fig.1 adapted 
from: http://en.wikipedia.org/wiki/Parkinson%27s_di sease). Additionally, other 
dopaminergic pathways are affected which explain the neuropsychiatric pathology of 
the disease.  
  13 
 
Fig.1 Dopamine pathway in normal brain (left side) and PD brain 
(right side). Red arrows indicate inhibiting pathways, blue arrows indicate 
stimulating pathways. In the normal brain, dopamine binds in equal amounts 
to dopamine receptors D1 (activating) and D2 (inactivating) in the putamen, 
which in consequence leads to stimulation of the cortex cerebri by the 
thalamus. In PD brain, reduced dopamine levels lead to excitation of the 
globus pallidus internus which inhibits excitatory activity of the thalamus. In 
consequence PD patients show hypokinesia.  
GPe…Globus pallidus externus, GPi…Globus pallidus internus, 
PUT…Putamen, SN…Substantia nigra, STN…Nucleus subthalamicus, 
THA…Thalamus 
 
1.1.3  Causes of PD 
 
Although Parkinson’s disease is a sporadic disorder of unknown cause, several 
factors have recently been discovered which correlate with the onset and progression 
of the disease. Several mutations in different genes causing PD symptoms have 
been identified.  
 
Although the direct cause of the sporadic disease is currently still unknown, many 
factors are believed to be involved in the induction of neuronal death. These factors 
include the aggregation of α-synuclein (caused by mutations, multiplication or 
abnormal processing), substrate accumulation, abnormal ubiquitination, generation of 
reactive oxygen species, inappropriate phosphorylation, protein misfolding and loss 
of cellular protection [5], [6] (Fig.2).  
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Fig.2 Parkinson’s disease factors leading to neuronal death. Factors leading to dopaminergic cell death 
include alpha-Synuclein aggregation to protofibrills and fibrils, substrate accumulation, abnormal ubiquitination, 
mitochondrial dysfunction, inappropriate phosphorylation, misfolded proteins and loss of cellular protection. 
Potential targets for therapy (blue circles): gene silencing (i), prevention of aggregation (i), down regulate toxic 
substrates (iii), enhance mitochondrial function (iv), radical scavengers and antioxidants (v), block LRRK2 kinase 
activity (vi), trophic factors or cell replacement (picture taken from Savitt et al. [5]). 
 
One of the most frequently detected genes mutated in familiar and sporadic PD is 
coding for the Leucine-rich repeat kinase 2 (LRRK2, PARKIN 8). So far six mutations 
in LRRK2 are associated with the disease  causing autosomal dominant PD [7]. 
Another gene found to be mutated, duplicated or triplicated in PD is α-synuclein [8]. 
In addition, loss of function mutations in the genes Parkin, DJ-1, PINK1 and 
ATP13A2 cause recessive late onset PD. Heterozygous loss of function mutations in 
the glucocerebrosidase (GBA) gene increase the risk to develop PD [9].  
Toxins including pesticides and metals like iron and manganese are causative for 
development of PD [10]. Finally factors like brain injury, rural living, lack of exercise, 
well-water ingestion and middle-age obesity are additional risk factors of PD [1], [11].  
 
  15 
1.1.4  Diagnosis 
 
A challenge for PD diagnosis is the overlap of symptoms with other 
neurodegenerative diseases (e.g. Alzheimer’s disease) and the sub-classification of 
the disease. Clinically the most prominent symptom of PD is bradykinesia (slowness 
of initiation of voluntary movement and reduction in speed of repeated actions [1]; 
and should always be diagnosed if no specific other cause is present. Additionally 
resting tremor (4-6 Hz), muscular rigidity, postural instability and good response to L-
dopa help to confirm diagnosis.  
Finally combining traditional with novel molecular biological methods or PET scan 
techniques will  help to properly diagnose the disease.  
 
1.1.5  Therapy 
 
Currently no drug is available for PD patients curing the cause of the disease. Only 
symptoms caused by the disease can be alleviated. At present L-dopa (Levodopa, L-
3,4-dihydroxyphenylalanine) a precursor of dopamine, noradrenalin, adrenaline and 
melanin, combined with dopamine agonists and peripheral dopa decarboxylase 
inhibitors (benserazide or carbidopa; prevent metabolism of L-dopa) are used to 
compensate for the dopamine deficit thereby reducing PD symptoms. Usually 
patients get 300-600 mg/day in the first five years of the disease improving 
bradykinesia, rigidity, gait, swallowing, speech, postural instability and fatigue. 
Tremor symptoms can, if at all only be reduced after long time drug therapy [12]. 
Adverse effects of this drug therapy include nausea, anorexia and faintness. 
Dopamine-agonists (pramipexole, ropinirole, rotigotine and piribedil) activate 
dopamine receptors and substitute the function of L-Dopa causing the similar 
adverse events except of dyskinesias. Mainly patients under the age of 55 years 
receive this drug [1]. To reduce the early wearing-off of L-dopa activity patients 
additionally receive COMT inhibitors (Catechol-O-methyl transferase inhibitor; 
entacapone)  and MAO-B inhibitors (Monoamine oxidase inhibitors; selegiline or 
rasagiline) [13]. COMT and MAO-B enzymes are usually responsible for degradation 
of dopamine, prevention of reaction leads to an increased half-life of dopamine in the 
synaptic cleft. Other therapeutic strategies include physical exercise and therapy, 
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logopedic therapy (to improve speech and swallowing) and occupational therapy (to 
improve everyday life).  
As mentioned above mutati ons in the Leucine-rich repeat kinase 2 ( LRRK2) gene are 
associated with most cases of  familial autosomal  dominant PD [14].  
 
1.2 Leucine-rich repeat kinase 2 (LRRK2) 
LRRK2 gene is located in the human genome on the long arm of chromosome 12 
(12q12) composed of 51 exons (Entrez GeneID: 120892). The mRNA is 7 kb of size 
coding for a protein of 2527 amino acids. The LRRK2 protein is a multi-domain 
protein with approximately 280 kD.  
People carrying mutations in this gene develop clinical symptoms that are 
indistinguishable from familial or sporadic late-onset PD. Until now there are several 
mutations in the LRRK2 protein known leading to pleomorphic pathology and 
autosomal dominant inheritance [15].  
 
1.2.1  LRRK2 domains 
 
The LRRK2 protein is composed of several domains with different functions. Starting 
with the N-terminus of the protein there is an ankyrin domain (ANK), the leucine-rich 
repeat (LRR), the Ras of complex (GTPase; ROC), the C-terminus of ROC domain 
(COR), the MAPKKK domain (mitogen-activated protein kinase kinase kinase; 
serine/threonine kinase) and the WD40 domain [16]. The ANK, LRR and the WD40 
domains are responsible for protein/protein interactions with cytoskeleton proteins, 
transcriptions factors and proteins regulating signaling and cell cycle. The MAPKKK 
domain shows sequence homology to members of the serine/threonine kinase family 
which regulate cell survival and cell-death in response to intra- or extra-cellular 
signals [17], [18]. The ROC and COR domains have sequence homology with 
members of the ROCO fami ly (GTPases). 
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Fig.3 Kinase activity regulation by 
ROC domains. Dimeric formation of the 
ROC domains (green and yellow) bind 
GTP (star) which leads to further 
dimerisation of COR and kinase 
domain. Hydrolysis of the GTP activates 
kinase domains, the produced GDP 
induces conformational changes with 
resulting separation of the dimers. 
(picture taken from Deng et al. [19]) 
 
The function of the COR domains has to be clarified, the ROC GTPase domain 
seems to have regulatory functions in vesicle formation, vesicle movement on the 
cytoskeleton and membrane fusion [20]. The GTPase activity needs dimerisation of 
the two ROC domains for GTP hydrolysis and activation of the MAPKKK domain [19] 
[21] (Fig.3). Although the functions of the different domains are known, the cellular 
function of LRRK2 protein remains elusive.  
 
1.2.2  Mutations 
 
Several missense mutations were found in the LRRK2 gene accounting for up to 
13% of familial PD and 5% of sporadic PD [22], [23] (Fig 4). This number is 
unexpected ly high for a disease that was thought not to be genetically determined. 
These autosomal dominant mutations are leading to the same phenotype in 
homozygous and heterozygous patients. PD relevant mutations are mainly located in 
the kinase (MAPKKK) and the GTPase domain (Roc-COR domain), leading to 
increased kinase activity [24].  
The most prevalent mutation found to date in the Mediterranean countries is the 
G2019S mutati on in the kinase domain, leading to increased enzymati c activity [25].  
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Of note not all mutations lead to increased activity. R1441C and R1441G mutations 
decrease GTPase activity and result in increased kinase activity [21]. The mutations 
R1941H, I2012T, I2020T and G2385R inhibit kinase activity including auto-
phosphorylation and phosphorylation of MBP (myelin basic protein) and moesin. The 
mutations Y1699C and T2356I have no effect on catalytic activity [26]. In contrast 
Gloeckner and co-workers found that in their experiments the mutations Y1699C and 
I2012T are able to increase kinase act ivity [27]. Also other functional properties of the 
LRRK2 protein are affected by mutations including protein interaction domains which 
in consequence alter enzymatic activity [28].  
Although a lot of studies were performed to clarify the function of LRRK2 domains 
still contradictory results remain in the literature.  
 
 
1.2.3  Interaction partners 
 
As mentioned above, the LRRK2 protein shows enzymatic activity as a dimer. 
Interaction motives include the ROC domain, the LRR domain the WD40 motive and 
N-terminal regions (Deng et al.; PNAS 2008; 105(5):1499-504). LRRK2 interacts with 
the cytoskeleton (α/ß tubulin of microtubules and vimentin) and cytoskeleton 
associated proteins [29]. These proteins include moesin, ezrin and radixin, which link 
the actin-cytoskeleton to the plasma membrane [26]. 
 
Fig.4 LRRK2 domains and mutations. Starting from the N-terminus the first domain is the ankyrin domain 
(ANK) followed by the leucine-rich repeat domain (LRR) (both protein/protein interaction domains), then the Ras 
of complex domain (Roc; GTPase), the C-terminus of Roc (COR), the MAPKKK domain and the protein/protein 
interaction domain WD40. Indicated are amino acid substitutions linked with the pathology (magenta), mutations 
that are not linked with the disease (green) and the corresponding exon location (black). Numbers beneath 
indicate the approximate boundaries of the domains. (picture from Mata et al., [16]) 
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Another LRRK2 interacting protein is clathrin, which is involved in vesicle formation 
[30]. Interaction could also be detected with the Rab5a protein involved in retrograde 
vesicle transport [31]. 
LRRK2 protein also seems to interact with chaperons like Hsp90 and other proteins 
involved in phosphorylation and protein translation [30].  
Proteins involved in neurodegenerative diseases were also tested for interaction with 
LRRK2 protein. LRRK2 interacts with parkin, a protein of the E3 ubiquitin ligase 
complex, responsible for ligation of ubiquitin residues on proteins, targeting them for 
degradation. Interestingly LRRK2 does not interact with α-synuclein, tau or DJ-1, 
proteins found to be involved in fam. PD [32]. Recent studies could demonstrate that 
LRRK2 protein interacts with elements of the extrinsic cell death pathway including 
Fas-associated protein with death domain (FADD) and Caspase-8. Mutations in the 
LRRK2 gene were also shown to trigger this pathway leading to increased cell death 
after application of H2O2 as external stress signal [33]. 
 
1.2.4  Localization 
 
In the brain, the LRRK2 protein is constitutively expressed in neurons, as well as in 
astrocytes and microglia cells, although at a lower level [34]. Cells expressing the 
LRRK2 protein are mainly located in the cerebral cortex, caudate-putamen, 
hippocampus and in dopaminergic neurons of the substantia nigra pars compacta 
[35], [36]. Paisán-Ruíz and coworkers (2004) could also detect LRRK2 expression by 
Northern Blot in other tissue such as liver, lung, heart and kidney [14].  
In the cell, LRRK2 is mainly localized in the cytoplasm where it associates with lipid 
rafts, early endosomes, mitochondrial membranes, lysosomes, synaptic vesicles, 
cytoskeleton, golgi apparatus and the endoplasmic reticulum [37].  
Colocalization of the LRRK2 protein with membranes and its association with 
cytoskeletal  proteins implies that LRRK2 might play a role in membrane trafficking 
[37].  
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1.2.5  Cellular effects of LRRK2 mutations 
 
The toxic effects of the LRRK2 protein in-vitro are generated by altered kinase 
activity [25]. Dopaminergic cell lines and primary neurons with increased kinase 
activity, resulting from LRRK2 mutations (e.g. G2019S), show increased apoptosis 
[38]. In contrast, a decreased kinase activity caused by altered ROCO and kinase 
domain (e.g. D1994N, DY2017-2018AL and K1906A), leads to reduced neuronal cell 
death.  
Another cellular effect of the LRRK2 protein is the kinase dependent neurite 
outgrowth. MacLeod et al. [39] showed a reduced dendritic outgrowth and branching 
of axons and dendrites in primary neuronal cultures when LRRK2-kinase activity was 
increased. Cells expressing LRRK2 protein harboring mutations in the kinase domain 
(G2019S, I2020T) and ROC domain (R1441G) all showed this reduction, while cells 
expressing mutant proteins with mutations located within the COR domain like 
Y1699C or cells over-expressing wild-type LRRK2 showed no significant alterations 
[39].  
 
1.2.6  Animal models 
 
Until now just a few transgenic animals over-expressing wt and mutant LRRK2 are 
described.  
Transgenic Drosophila were generated, expressing wt and mutant LRRK2 [40]. Flies 
with mutant LRRK2 show late onset loss of dopaminergic neurons and a reduced 
lifespan.  
A transgenic mouse line with an N-terminal truncated form of human LRRK2 under 
Thy1.2 promoter was generated (E. Masliah, personal communication) but no 
obvious defect has been reported until  now.  
Recently, Li and coworkers developed a transgenic mouse-line over-expressing 
human LRRK2-R1441G from a bacterial artificial chromosome (BAC). Transgenic 
animals show some of the cardinal features of the disease, including age-dependent 
and L-dopa-responsive slowness of movement and reduced dopamine release in 
CNS. In contrast a mouse line over-expressing wild-type human LRRK2 did not 
develop age-dependent motor  deficits [41].  
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The observed phenotypes and molecular alterations in these models are typical for 
PD-like neurodegeneration. Therefore a detailed analysis is required to evaluate 
whether LRRK2 is a target for potential  novel treatment strategies against PD.  
Therefore, a transgenic mouse line over-expressing human LRRK2 has been 
developed recently.  
Aim of the diploma thesis was the expression analysis of the vector used for 
transgene production and an initial characterization of the transgenic animals over-
expressing full length, wild type, human LRRK 2. 
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2 MATERIALS AND METHODS 
2.1 Cloning and p lasmid expression analysis 
2.1.1  Eukaryotic expression vector pCMV6-XL5-LRRK2 
(ORIGENE) 
 
Human LRRK2 cDNA (7,7 kb) was cloned into the NotI site of the MCS of pCMV6-
XL5 performed by ORIGENE. LRRK2 CDS is under control of the CMV promoter 
allowing high expression in eukaryotic cell types. This vector was used for 
transfection into CHO and HEK 293 cell s to test LRRK2 expression.  
 
 
Fig.5 pCMV6-XL5 plasmid (taken from 
http://www.origene.com/cdna/trueclone/vectors.m
spx). Not I digestion and integration of LRRK2 
gene into MCS for expression analysis. Ampr, 
selection marker in E.coli; CMV promoter, 
cytomegalovirus promoter for in vivo expression in 
mammalian cells; SV40 ori, replication in 
mammalian cells; ColE1, bacterial origin of 
replication; F1 ori, filamentous phage origin of 
replication; T7 promoter, in vitro transcription 
 
 
2.1.2  Expression vector pUC18-Thy1.2-LRRK2 (Polygene) 
 
Plasmid pUC18-Thy1.2-LRRK2 contains a Thy1.2 promoter normally coding for a 
glycophosphatidyl inositol linked surface protein expressed in cells of thymus, 
nervous system and connective tissue. The modified Thy1.2 promoter with integrated 
LRRK2 CDS allows specific expression in nervous system and in the lung [42]. 
Cloning was performed by Polygene. This vector was used to test expression of 
LRRK2 in cells and for generation of hLRRK2 transgenic mice.  
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Fig.6 pUC18-Thy1.2-LRRK2 plasmid XhoI integration site of LRRK2 cDNA with intact 
Kozak consensus sequence and full length, non-interrupted ORF. Complete length of 
the plasmid with LRRK2 cDNA (7,7 kb), Thy1.2 cassette and pUC18 backbone is 
~17kb. pUC18 vector contains bla gene, coding for ß-lactamase providing ampicillin 
resistance and the pMB1 replicon rep for plasmid replication. 
 
2.1.3  Transformation 
 
The process for introducing plasmid DNA into bacteria (DH5α) is called 
transformation.  
20 µl DH5α competent cells (Invitrogen) were thawed on ice for 5 minutes and mixed 
with 1 µl pCMV6-XL5-LRRK2 or Thy1.2-LRRK2 plasmid. Then DH5α were placed 
back on ice for 30 minutes and then incubated 2 minutes at 42°C. After that, bacteria 
were placed 3 minutes on ice, LB medium (Roth) was added and was incubated 1 
hour at 37°C. Then bacteria were pelleted (2000 rpm for 5 minutes) and resuspended 
in 100 µl fresh LB medium (Roth), 20 µl plated on LB agar containing ampicilin to 
select for transformed bacteria. Plates were incubated over night on 37°C to get 
single clones containing the plasmid.  
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2.1.4  Maxi prep - Plasmid DNA Purification with QUIAGEN 
Maxi Kit (Protocol from QIAprep Handbook) 
 
For cloning and transfection high amounts of vector DNA were needed. Therefore 
large volumes of transformed bacteria were cultivated to obtain enough plasmid for 
the planed experiments. Isolation of big amounts of plasmid DNA from bacterial 
cultures is called maxi prep.  
 
Bacterial culture, harvest, and lysis 
100 ml overnight LB culture was pelleted with 6000 x g for 15 min at 4°C. The pellet 
was resuspended in 10 ml buffer P1 (containing RNase A), then 10 ml buffer P2 was 
added and the solution was inverted for 4-6 times and incubated at room temperature 
for 5 minutes. After  that 10 ml buffer P3 was added and agai n inverted 4-6 times.  
 
Bacterial lysate clearing 
The lysate was transferred to a QIAfilter Cartridge and incubated at RT for 10 min. 
The cap was removed from the QIAfilter Cartridge outlet nozzle, the plunger inserted 
into the QIAfilter Maxi Cartridge and the cell lysate filtered into a 50 ml tube. After 
that 2,5 ml buffer ER was added to the filtered lysate, inverted 10 times and 
incubated 30 minutes on ice. 
 
Binding, wash and el ution of the plasmid DNA 
The QIAGEN-tip 50 was equilibrated by applying 10 ml Buffer QBT and allowed the 
column to empty by gravity flow. The filtered lysate was applied to the QIAGEN-tip 
and allowed it to enter the resin by gravity flow. After that the QIAGEN-tip was 
washed with 2 x 30 ml buffer QC. DNA was eluted wi th 15 ml Buffer QN. 
 
Precipitation, wash and redissolving of the plasmid DNA 
DNA was precipitated by adding 10,5 ml isopropanol to the eluted DNA and mixed. 
Then the solution was centrifuged at 15,000 g for 30 min at 4°C and the supernatant 
carefully decanted. The DNA pellet was washed with 5 ml of endotoxin-free room-
temperature 70% ethanol and centrifuged at 15,000 g for 10 min. The supernatant  
was again decanted carefully and the pellet air dried for 5-10 minutes. DNA was 
redissolved in endotoxin-free buffer TE.   
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Determination of DNA concentration in the eluate was done by measurement of 
optical density (OD) with 260 nm wavelength (Photometer , Perkin Elmer Lambda 2) .  
 
OD260 nm 1 = 50 µg / ml = 50 ng / µl 
2.1.5  Restriction enzyme digestion 
 
Restriction enzyme digestion was done from Maxi-prep DNA eluates. Enzyme NotI 
(Fermentas) was used for plasmid pCMV6-XL5-LRRK2 to cut out the LRRK2 gene 
(7kb) from the vector. For plasmid pUC18-Thy1.2-LRRK2 endonucleases Pvu I 
(Fermentas), Xho I (Fermentas), EcoR V (New England BioLab), EcoR I (Fermentas) 
and Hind III (Fermentas) were used independently for analysis. 1 µg plasmid DNA 
was incubated for  1 hour at 37°C with 10 u of enzyme. Then samples were loaded on 
1% Agarosegel with SYBRsafe (Invitrogen) and run with 100V for 2 hours. Imaging 
was done wi th UV-trans-illuminator to detect DNA bands.  
 
2.1.6  PCR 
 
In the polymerase chain reaction sequence specific primers bind to DNA and allow 
amplification by Taq polymerase (Promega 5u/µl). Different templates were used, 
including DNA from bacteria, DNA from cell culture and genomic DNA from mice. 
Primer pairs used for analysis are listed below.  
Reagents used for one PCR r eactions were mixed in 200 µl thin wall PCR tubes:  
 
Reagents volumes 
Template DNA 1,00 µl 
10x reaction mix (Roche) 2,50 µl 
Taq polymerase 0,25 µl 
10mM dNTPs (Promega) 0,50 µl 
MgCl2 (50 mM) 1,00 µl 
Forward primer  0,50 µl 
Reverse primer 0,50 µl 
MiliQ water 18,75 µl 
            25,00 µl / reaction 
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Tubes were placed into Biometra T3 Thermocycler and PCR was performed as 
follows: 
 
· 90°C for 2 min. (DNA-denaturation step) 
· PCR amplification: 35 cycles of:  
90°C for 15 sec. 
57°C for 30 sec. 
72°C for 1 min. 30 sec. 
· Final extension:  
72°C 5 min. 
4°C hold 
 
2.1.7  Semi-quantitative PCR 
 
For determination of the approximate amount of LRRK2 transgene in genomic DNA 
samples, semi-quantitative polymerase chain reaction (sqPCR) was done. Primers 
used for internal control were specific for the control gene mGAPDH, LRRK2 specific 
primer 4/5 were used for transgene detection (details below). PCR conditions used 
were the same as mentioned above, but an aliquot for subsequent analysis was 
taken after 16, 18, 21, 24, 27, 30, 33 and 36 cycles.  
 
2.1.8  Quantitative PCR with iQ SYBR green Supermix (BIO 
RAD) 
 
Quantitative PCR (qPCR) was either used to determine the amount of LRRK2 
transgenes in gDNA of transgenic mice, or to analyse LRRK2 RNA expression 
compared to an internal control gene. This method detects the amount of 
synthesised dsDNA in a PCR reaction in real time. We used the fluorochrome SYBR 
green (BIO RAD) which intercalates with dsDNA only to detect increasing amounts of 
dsDNA dur ing synthesis.  
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Samples were combined with primers and iQ SYBR green Supermix (BIO RAD) in 
tubes and analysed in the MyiQ Cycler (BIO RAD).  
 
2x iQ SYBR green Supermix (BIO RAD) 
100 mM KCl 
40 mM Tris-HCl; pH8 
0,4 mM  of each dNTP 
50 U/ml iTaq DNA Pol . 
6 mM MgCl2 
20 nM fluoresceine SYBR Green I 
Stabilizers 
 
PCR condi tions 
3 minutes 95°C (initial denaturation step) 
 40 repeats of:  
10 sec. 95°C 
20 sec. 57°C (anneal) 
20 sec. 72°C (PCR) 
6 sec.  80°C (Real time) 
 Melting curve (57 steps) 
6 sec.  55,0-94,2°C (0,7°C temperature steps) 
 
After PCR, results were analysed with the MyiQ cycler software (BIO RAD) and 
additionally by conventional gel electrophoresis.  
 
2.1.9  Primer 
 
Primers used for  PCR, RT-PCR, sqPCR and qPCR were synthesi sed by Microsynth.  
 
Primers specific for control genes: 
 
· IL2 primer (gDNA) 
forward: 5´-CTA GGC CAC AGA AT T GAA AGA TCT-3´ 
reverse: 5´-GTA GGT GGA AAT TCT AGC ATC ATC-3´ 
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· Rpl32 primer (cDNA) 
forward: 5´-CCA TCT GTT TTA CGG CAT CA-3´ 
reverse: 5´-ATT GTG GAC CAG GAA CT T GC-3´ 
 
· mGAPDH primer (mouse, NM_001001978 ) (cDNA) 
forward: 5´-GAG TAT GTC GTG GAG TCT ACT GG-3´ 
reverse: 5´-CCA TCC ACA GTC TTC TGG GTG GCA-3´ 
 
Transgene specific primers used bind to the human LRRK2 coding sequence (cDNA) 
in the plasmid and to the expressed LRRK2 mRNA. These primers are able to detect 
presence of the transgene on DNA and RNA level. Two different primers were used 
for analysis, one binding to the N-terminus and one to the C-terminus of the 
transgene. Hence,  it is possible to detect full length hLRRK2 DNA and mRNA.  
 
Primer binding to the N-terminus of the LRRK2 gene:  
 
LRRK2 fw1: 5´-TCATTTCCAGCCAATGATGA-3´ 
LRRK2 rev1: 5´-TGGAGCAAACAGAA CTCAC-3´ 
 
Primer binding to the C-terminus of the LRRK2 gene:  
 
LRRK2 fw4: 5´-ATTCAACGGAAAGAAAT GTAATG-3´ 
LRRK2 rev5: 5´-TTCTGCTTTTGTGTACCTTCAGTAT-3´ 
 
2.1.10 Gel electrophoresis 
 
Gel electrophoresis was used to separate DNA or RNA in an agarose gel with 
respect to different size. A 1% agarose (Invitrogen) gel in 1x TAE was used for 
analysis. For detection of the nucleic acid the intercalating reagent SYBR safe 
(Invitrogen) was added to liquid agarose before the gel was casted. Samples for gel 
electrophoresis were mixed with loading buffer and separated by 10V/cm of the gel. 
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DNA ladder used as standard was FastRuler DNA ladder low range (Fermentas). 
The UVP UV-Transilluminator was used for  detection of DNA/RNA signal s.  
 
50 x TAE: (1 liter) 
242 g  TRIS (Roth) 
57,1 ml  Acetic acid 
100 ml 0,5 M  EDTA (pH 8,0) (Roth) 
 
Loading buffer (6x) 
10mM  Tris-HCL (pH 7,6) (Sigma) 
0,15 %  Orange G (Sigma) 
0,03 %  Xylene Cyanol  (Sigma) 
60 %  Glycerol (Roth) 
60 mM  EDTA (pH 8,0) (Sigma) 
 
2.1.11 SuperScriptTM One-Step RT-PCR with Platinum Taq 
(Invitrogen)  
 
This method combines reverse transcription and PCR in a single reaction catalysed 
by SuperScriptTM II Reverse Transcriptase and Platinum Taq DNA Polymerase 
(Invitrogen).  
 
cDNA synthesi s and pre-denaturation: 
50°C for 30 min 
94°C for 2 min 
 
PCR amplification: 35 cycles repeat 
94°C for 15 sec (denatur e),  
54°C (fw1/rev1) or 52°C (fw4/rev5) for 30 sec (anneal) 
72°C for 30 sec 
 
Final extension:  
72°C for 5 min 
Hold 4°C 
PCR samples were loaded on 1 % agar ose gel to detect amplified products.  
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2.1.12 Cell culture 
 
Cell lines: 
Three different cell lines were used for analysis of plasmid expression on RNA and 
protein level. All cells were cultivated in cell culture flasks (Greiner bio-one 75 cm²) at 
37°C in a humidified atmosphere with 5% CO2 (Tissue culture incubator, Salvis).  
 
Cells and medium: 
· Chinese hamster  ovary cells (CHO cells)  
Medium (500 ml):  
· Iscove´s Modified Dulbecco´s Medium (IMDM, Gibco) 
· 10% foetal  calf serum (FCS, Gibco) 
· 100 U/ml penicillin (Invitrogen) 
· 100 µg/ml streptomycin (Invitrogen) 
· 5 ml non-essential-amino acid (NEAA) 100x (Invitrogen) 
· 5 ml Na-pyruvat 100 mM (Sigma) 
· 2 ml gentamycin (Invitrogen) 
 
· Human embryonic kidney cell s (HEK 293) 
Medium (500 ml):  
· Dulbecco´s Modified Eagle Medium (DMEM, Gibco) 
· 10% FCS (Gibco) 
· 2mM L-glutamine (PAA) 
· +10 ml Pen/Strep (Invitrogen) 
 
· SH-SY5Y cel ls (Neuroblastom cell  line) [43] 
Medium (500 ml): 
· 1:1 F12 nutrient mixture (Gibco) and IMDM 
· 10% FCS (Gibco) 
· +10 ml Pen/Strep (Invitrogen) 
· +5 ml NEAA 
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2.1.13 Cell thawing 
 
For thawing of cells, incompletely thawed cells were added to 10 ml pre-cooled 
medium. Then, cells were centrifuged 5 minutes with 800 g (Heraeus SEPATECH 
Magafuge 1.0), supernatant was removed and the pellet dissolved in 20 ml medium 
and transferred into cell culture flasks (Greiner bio-one 75 cm²) and grown at 37°C in 
a humidified atmosphere with 5% CO2 (Tissue culture incubator, Salvis).  
 
2.1.14 Cell splitting 
 
Medium was removed from approximate 90% confluent cells (nearly 3 times/week) 
and washed with 1xPBS (Gibco). Then cell dissociation solution (Sigma) was added 
to the cells and briefly incubated at 37°C in the incubator. When cells detached from 
the surface, medium was added and transferred to fresh 50 ml tubes. Cells were 
centrifuged with 800 g for 5 minutes and the supernatant removed. The pellet was 
dissolved in fresh medium and cells were diluted in 1:1, 1:5 and 1:10 dilutions in cell 
culture flasks (Greiner bio-one 75 cm²).  
 
2.1.15 Cell cryoconservation 
 
Cells were detached with 2 ml cell dissociation solution (Sigma) then 3 ml medium 
was added. Cells were pelleted by 5 minutes centrifugation with 800 g and dissolved 
in 1800 µl medium/10 % DMSO (Fluka). For storage, cells were placed in cryotubes 
at -80°C.  
 
2.1.16 Lipofectamine Transfection (Invitrogen) 
 
For transfection cells were grown to 60- 80 % confluence in a 6-well plate (Greiner 
bio one; 9,5 cm2 growth area, Ø 34,8 mm).  
Before transfection, growth medium was replaced by 1 ml of serum free medium. 
DNA was pre-complexed with the PLUS-Reagent by dilution of 1,6 µg DNA in 125 µl 
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serum-free medium (without antibiotics), 20 µl PLUS-Reagent and incubation for 15 
minutes at room temperature. 10 µl Lipofectamine Reagent was diluted in 125 µl 
serum-free medium, added to the pre-complexed DNA and incubated for additional 
15 minutes at room temperature. Then the DNA-PLUS-Lipofectamine Reagent 
complexes were added to the cells, mixed gently and incubated at 37°C in the 
incubator for 4 hours. After 4 hours 1 ml serum containing medium was added to the 
cells and incubated for 24 hours at 37°C. After that cells were used for further 
analysis.  
 
2.1.17 Immunocytochemistry 
 
For immunocytochemistry, cells were grown on culture slides (VWR) until 80-90 % 
confluence and transfected as described above. Medium was removed and cells 
were washed 2 times carefully with 1xPBS. For fixation, pre-cooled methanol (Roth) 
was added to the cells and incubated at -20°C for 10 minutes. Then, cells were 
washed 3x with 1xPBS and blocked with 10 % normal goat serum in 1xPBS/0,25 % 
Triton X-100 (Fluka). Primary antibody incubation (diluted in blocking solution) was 
done over night on 4°C. The following day, cells were washed 5 x with 1xPBS and 
incubated for 1 hour with secondary antibody (1:250 diluted in blocking solution). For 
fluorescence staining cells were mounted in vectashield DAPI-mounting medium 
(Vector). For DAB staining, cells were incubated with ABC solution (Vector) for 30 
minutes, washed and incubated with DAB substrate (Vector), and counterstained 
with haematoxyl in. Cells were covered by Cytomation Glycergel mounting medium 
(Dako) and mounted. Finally slides were evaluated under a microscope (Leitz 
DIAPLAN) with 40x magnification.  
 
1st antibody (diluted in 10 % normal goat serum in PBS/0,25 % T riton X-100) 
· NB 300-268 rabbit polyclonal anti-LRRK2 antibody (Novus Biologicals) 
 
2nd antibody (diluted in 10 % normal goat serum in PBS/0,25 % T riton X-100) 
· Biotinylated goat anti-rabbit antibody (Vektor) 
· Goat anti-rabbit antibody Texas red (Vektor) 
 
  33 
2.1.18 RNA-Extraction from cell culture with RNeasy Kit 
from QUIAGEN (protocol from QUIAGEN RNeasy 
Handbook) 
 
Cells used for RNA extraction were cultivated in 6-well plates until ~90% confluence. 
When starting with purification of total RNA cell culture medium was replaced by 350 
µl RLT buffer (10 µl 14,3 M ß-mercaptoethanol  per 1ml RLT). A rubber polishmen 
was used to detach the cells from the surface and then cells were transferred into a 
fresh RNase-free tube. After that 350 µl 70% ethanol was added and the solution 
was mixed by pipetting. 700 µl suspension was transferred to the RNeasy spin 
column. The homogenate was centrifuged 15 sec. with 10.000 g to bind RNA to the 
column, the flow through was discarded. Then 700 µl RW1 buffer was pipetted onto 
the column and again centrifuged 15 sec. with 10.000 g. After that two times 500 µl 
RPE buffer was loaded and centrifuged under the same conditions. For elution, the 
column was placed in a fresh tube and 50 µl RNase-free water was added to the 
column and centrifuged 1 min. with 10.000 g.  
RNA concentration was determined by measurement of optical density (OD) at 260 
nm wavelength (photometer, Perkin Elmer Lambda 2) .  
 
OD260 nm 1 = 40 µg / ml = 40 ng / µl 
 
2.1.19 DNase treatment (Promega) 
 
RNA from cell culture and animal tissue was treated with RQ1 RNase-free DNase I 
(Promega) to remove genomic and plasmid DNA from the samples. DNA 
contamination had to be eliminated to get RNA specific signals in PCR and qPCR.  
To assess the correct amount of DNase for the used samples (1 unit DNAse per 1 
microgram RNA), RNA concentration was determined by NanoDrop (Thermo 
Scientific. DNase treatment was done for 30 minutes at 37°C in DNase Reaction 
Buffer (400 mM Tris-HCl pH 8, 100 mM MgSO4, 10 mM CaCl2; Promega). Reaction 
was stopped by adding 1 µl RQ1 DNase Stop Solution (20 mM EGTA; Promega) to 
the samples and incubation at 65°C for 10 minutes to inactivate the DNAse.  
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2.1.20 cDNA synthesis with Super Script First-Strand 
Synthesis System for qPCR (Invitrogen) 
 
DNase treated and untreated RNA samples were used for cDNA synthesis. To proof 
the purity of RNA samples and exclude DNA contamination, samples were run in 
duplicates whereas in only one sample reverse transcriptase was added. 
Synthesised cDNA was used as templ ate for PCR and Q-PCR.  
For RT reaction, RNA was added to t he Oligo dT synthesis mix: 
 
total RNA (5 µg) x µl 
dNTP (10 mM) 1 µl 
oligo dT primer 1 µl 
DEPC water up to 10 µl 
 
The RNA/oligo dT mixture was incubated for 5 minutes at 65°C in the T3 
thermocycler (Biometra) and then placed on ice. Afterwards, 9 µl reaction mix was 
added to the sampl es: 
 
10x RT buffer 2 µl 
25 mM MgCl2 2 µl 
0,1 M DTT 2 µl 
RNase OUT (40 U/µl) 1 µl 
DEPC water 2 µl 
Total volume 9 µl 
 
Samples were placed in the thermocycler (Biometra T3) for 2 minutes at 42°C and 1 
µl Super Script II RT (Invitrogen) was added to one tube of the duplicates. Then all 
samples were incubated for 50 minutes at 42°C for cDNA synthesis and 15 minutes 
at 70°C to terminate the reaction. After cooling 1 µl RNase H (Invitrogen) was added 
and incubated for 20 minutes at 37°C for  degradation of the RNA.  
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2.1.21 Protein extraction from eukaryotic cells 
 
For protein extraction, medium was removed and cells were washed two times with 
1xPBS (Gibco). Then 100 µl RIPA buffer was added to each well, cells were 
detached with a cell scraper and transferred to a fresh tube. Cells were vortexed 
thoroughly and incubated on ice for 20 minutes. After that, lysate was centrifuged 10 
minutes at 4°C with 13.000 g. The supernatant was collected and stored at -80°C 
(quick frozen in liquid nitrogen).  
 
RIPA buffer  (radio immunoprecipitationassay buffer) 
50 mM Tris pH 7,4 
150 mM NaCl (Roth) 
1 % Triton-X100 (Sigma) 
0,5 % Sodium-deoxycholate 
5 mM EDTA (Sigma) 
 
Working solution: 
9 ml  RIPA buffer  
1 ml  NaF (Sigma) 
100 µl  100x NaOV (Sigma) 
 
2.1.22 Bradford protein assay 
 
Determination of protein concentration in a homogenate was done by Bradford 
assay. The dye reagent changes from red to blue by cationic and hydrophobic 
protein binding with an absorbance maximum at 595 nm wavel ength.  
For analysis the dye reagent concentrate (BioRad) was diluted 1:5 with miliQ-Water 
(Millipore) and filtered through a Whatman filter to remove precipitates. BSA (2 
mg/ml; Pierce) serial dilutions were used as a standard (concentrations see below).  
Samples were diluted 1:10 and 1:20 and used in duplicates. 10 µl BSA standard or 
protein samples were pipetted on micotiterplates (Nunc) and 200 µl dye reagent was 
added and mixed. Plates were incubated at room temperature for 5 minutes and then 
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absorbance was measured at 595 nm wavelength with a plate reader (Tecan 
Sunrise).  
 
Standard Protein conc.  Volume H2O volume BSA standar d 
Original ............. 2,00 mg/ml .................... - ................................ .1 ml glass vial 
St 1.................... 0,50 mg/ml ............... 150 µl ............................... 50 µl original 
St 2.................... 0,40 mg/ml ................. 10 µl ................................ .... 40 µl St 1 
St 3.................... 0,30 mg/ml ................. 20 µl ................................ .... 30 µl St 1 
St 4.................... 0,20 mg/ml ................. 30 µl ................................ .... 20 µl St 1 
St 5.................... 0,10 mg/ml ................. 40 µl ................................ .... 10 µl St 1 
St 6.................... 0,05 mg/ml ................. 45 µl ................................ ...... 5 µl St 1 
Blank ................. 0,00 mg/ml ................. 50 µl ................................ .................. - 
 
2.1.23 SDS polyacrylamide gelelectrophoresis (SDS PAGE) 
 
For the separation of proteins a polyacrylamide gel containing SDS was used, 
separating the molecules according to their molecular size.  
For analysis a 4% acrylamide stacking gel  and 7% acrylamid running gel was casted.  
 
7% running gel 
MiliQ H2O (Millipore) 15.150 ml 
1.5 M Tris-HCl, pH 8.8 (Sigma) 7.500 ml 
10% (w/v) SDS (Fluka) 0.300 ml 
30% Acrylamide (Roth) 6.900 ml 
10% (w/v) ammonium persulphate (Roth) 0.150 ml 
TEMED (Roth) 0.020 ml 
 
4% stacking gel 
MiliQ H2O (Millipore) 3.050 ml 
0.5 M Tris-HCl, pH 6.8 (Sigma) 1.250 ml 
10% (w/v) SDS (Roth) 0.050 ml 
30% Acrylamide (Roth) 0.670 ml 
10% (w/v) ammonium persulphate (Roth) 0.025 ml 
TEMED (Roth) 0.005 ml 
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1x running buffer 
 
25 mM  Tris-HCl (Sigma) 
200 mM  Glycine (VWR) 
0.1% (w/v)  SDS (Fluka) 
 
Polymerized gels were placed in western gel gadget and filled with 1x running buffer. 
Samples from cell culture or animal tissue were mixed with Sample buffer, incubated 
at room temperature (not heated!) for 10 minutes and 20 µg loaded on the SDS gel. 
As positive control 5 µg recombinant LRRK2 protein (205 kD, aa 970-2527, 
Invitrogen) was loaded on the gel .  
 
5x sample buffer 
 
10% w/v SDS (Fluka) 
10 mM ß-mercaptoethanol  (Sigma) 
20 % v/v Glycerol (Roth) 
0.2 M Tris-HCl, pH 6.8 (Sigma) 
0.05% w/v Bromophenolblue (Sigma) 
 
5 µl Protein ladder (PageRuler Plus prestained protein ladder / Fermentas, HiMark 
prestained protein standard / Invitrogen) was loaded to indicate the size. 
Electrophoresis was performed in the gel chamber (Biorad, MGV-202) 1 hour with 
150 V constant  (Power supply - Biorad, Power Pac).  
 
2.1.24 Western Blotting (WB) 
 
The samples were separated by SDS gel electrophoresis according to molecular 
size. Then proteins got transferred voltage-dependent on a 0,45 µm pore-size 
nitrocellulose membrane (Amersham Bioscience Hybond-C Extra) (Blot chamber – 
Mini Trans-Blot cell, Biorad). Fig.7 shows the sandwi ch model of the protein transfer.  
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Fig.7 Sandwich model for protein transfer. Negatively charged proteins migrate to 
the plus pole and bind to the membrane.  
 
Western Blotting was performed in transfer buffer over night at 4°C with 30V 
constant.  
 
10x transfer buffer (pH should be 8,3; d o not adjust) 
30.3 g Trizma base (= 0.25 M) (Roth) 
144 g  Glycine (= 1.92 M) (VWR) 
 
2 L 1x transfer buffer  
400 ml  Methanol  (Roth) 
200 ml  10x transfer buffer 
1400 ml  MiliQ H2O (Millipore)  
 
Ponceau staining was done to confirm complete protein transfer to the membrane. 
The membrane was used di rectly for further experiments or stored at 4°C unti l further 
use.  
Membrane was washed in PBST (1x PBS + 0,01 % Tween20 (Roth)) and blocked 1 
hour with 5% (w/v) milk in PBST. Then the membrane was incubated with the 
primary antibody diluted in 5 % milk/PBST for 1 hour at room temperature [44, 45], 
followed by 3 t imes 5 minutes washing with PBST to remove unspeci fic binding of the 
antibody. After that, membrane was incubated with the HRP conjugated secondary 
antibody diluted in 5 % milk/PBST for 30 minutes at room temperature and washed 
three times 5 minutes with PBST. ECL+ detection kit (GE Healthcare) was used for 
antibody detect ion. Signal was evaluated with UVP Bioimaging system.  
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After evaluation, the membrane was stripped with stripping buffer for 20 minutes at 
room temperature to remove primary antibody, washed briefly in PBST and used for 
another ant ibody incubation.  
 
Stripping buffer: 0.5 L 
0.2 M  Glycine, pH 2.5 (VWR) 
0.05%  Tween 20 (Roth) 
 
Primary antibody [44, 45] 
· Mouse 16H7-A5 anti-LRRK2 monoclonal antibody (AFFiRiS AG) (1:50) 
· NB 300-268 rabbit polyclonal anti-LRRK2 antibody (Novus Biologicals) 
1:1.000 
· Rabbit polyclonal anti LRRK2 antibody AB 9682 (Chemicon, Millipore) 
· Anti-TH (tyrosine hydroxylase) antibody 1:2.000  
· Rabbit polyclonal anti-ß actin antibody (Novus Biologicals) 1:1.000 
 
Secondary antibody 
· Goat anti-mouse-HRP IgG+IgM (H+L) (Jackson) 1:20.000 
· Anti-rabbit IgG-HRP (GE Healthcare) 1:10.000 
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2.2 Animal characterization 
 
2.2.1  Transgenic mouse line 
 
Transgenic animals were generated and bred by PolyGene according to their 
standardized method. Briefly, the isolated fragment was injected into zygotes and 
transferred into IVC-held foster mothers. C57Bl/6N offsprings were screened and 
verified by tail biopsy. Finally four transgenic founders, three male and one female 
animal paired with wildtype C57Bl/6N animals were received. Progeny of the founder 
animals was genotyped and analysed by behavioural tests and biochemical analysis 
for transgene expression. 
 
2.2.2  Behavioural analysis 
 
Behavioural analysis was done with 6 animals derived from crossing LRRK2-founder 
animals and wild type littermates (C57Bl/6N). Animals (3 wt, 3 tg) were tested on 4 
consecutive days. Four different tests wer e performed in this experiment. These tests 
are intended to analyse the motor function of these animals.  
 
Grooming 
The fur and the overall shape of the animals were inspected routinely. Reduced 
grooming activity might be indicative for motor or mental impairment.  
 
Challenging beam 
With this test, motor function (walking and balance) of the mice was tested. A plastic 
beam with 1m length and 5 -1,5 cm narrowing diameter covered with a grid was used.  
Mice had 2 t raining days (beam without grid) with 5 trials each. On the third day, mice 
performed the probe trial  with the grid, which was filmed for later evaluation. The total  
number of steps and the number of errors per steps (front and hind limbs) were 
counted.  
  41 
 
 
Fig.8 Beam test 
 
 
Fig.9 Beam with grid 
 
Pole test 
With this test the grip strength and climbing skills were monitored. A wooden pole of 
50 cm length and 1 cm diameter was wrapped with a gauze bandage. The time to 
turn around (U-turn-time), the time to descent (runtime) and the total time (maximum 
120 seconds) was reported. Behavioural test data from five repetitions per mouse 
were collected over  three days.  
 
 
Fig.10 Pole test 
Coordination and muscle 
function were tested. 
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Grip test 
The muscular strength was tested by placing the mice on the metal lid of the cage. 
The lid was inverted and placed on the top of two cylinders. Mice had to hang on the 
lid. The time until mice fell off was measured and after 2 minutes the test was 
stopped. The test was repeated three times for each mouse and the data was 
collected over three days.  
 
 
Fig.11 Grip test Endurance and muscle function were tested 
 
2.2.3  Genomic DNA purification (Wizard® Genomic DNA 
Purification Kit, Promega) 
 
For genotyping mouse tail tips were used for genomic DNA purification (genomic 
DNA purification system; Promega). Mouse tail tip (2-3 mm) was transferred into a 
1,5 ml tube. 275 µl digestion solution was added to each sample and incubated over 
night (16-18 hours) at 55 °C. The next day, 250 µl SV lysis buffer was added and 
vortexed. Mixture was transferred to the minicolumn and spinned for 3 minutes with 
13.000 g. The flow-through was discarded, 650 µl wash solution added to the column 
and centrifuged for 1 minute with 13.000 g. Washing was repeated for 3 times 
followed by centrifugation for 2 minutes at 13.000 g. Then matrix was dried by 2 
minutes centrifugation with 13.000 g. For elution, column was placed in a new 1,5 ml 
microcentrifuge tube and 250 µl  nuclease-free water was added on the matrix. After 2 
minutes incubation the column was centrifuged 1 minute with 13.000 g. This step 
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was repeated once using the eluate from the previous step, to increase DNA 
concentration. 
 
Digestion solution: 
Nuclei Lysis solution 200 µl 
0,5 M EDTA (pH 8) 50 µl 
Proteinase K 20 mg/ ml (Roche) 20 µl 
RNase A sol ution 5 µl 
 275 µl 
 
2.2.4  Genotyping PCR 
 
Genomic DNA from mouse tail tips was used for genotyping PCR to detect the 
presence of the transgene. Internal control primers used, were the IL2 primer (see 
above). For LRRK2 detection, LRRK2 primer 1 and LRRK2 primer 4/5 were used 
(see above) . PCR condi tions were the same for  all primer combinations (see above).  
 
2.2.5  Brain fixation and dehydration 
 
After preparation of mouse br ains one hemisphere was used for  biochemical analysis 
(RNA and protein extraction) and the other hemisphere was dehydrated and 
embedded in paraffin for microtome (Leitz 1516) sectioning.  
For tissue fixation, the brains were incubated in 4% PFA (paraformaldehyde) (VWR) 
over night on 4°C. The next morning: 
 
tissue was placed for 30 minutes in 1xPBS followed by stepwise 
dehydration: 
2 hours in 30 % ethanol  (Merck) 
1 hour in 30 % ethanol  
2 x 2 hours in 50 % ethanol 
70 % ethanol  for 2 days 
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Two days later: 
Fresh 70 % ethanol 1 hour  at room temperature 
2 x 1,5 hours in 90 % ethanol  
2 x 1,5 hours in abs. ethanol  
10 minutes in Xylene (beaker  glass) (Roth) 
Over night in liquid paraffin (incubator 60°C) 
 
The next day:  
Change paraffin in the morning 
Sagittal embedding at midday 
 
Tissue sections of 7 µm thickness were made with microtome (Leitz 1516) and 
placed on glass sl ides.  
 
2.2.6  Immunohistochemistry 
 
PFA fixed brain sections (see above) were placed in xylene 2 x for 10 minutes to 
remove the paraffin. After that tissue had to be rehydrated: 
 
2 x 10 minutes in abs. ethanol 
2 minutes in 70 % ethanol  
2 minutes in 50 % ethanol  
2 minutes in 30 % ethanol  
2 minutes in miliQ H2O (Millipore) 
 
Antigen-retrieval was done with Citra solution (DAKO) in the microwave for 3 minutes 
at maximum power and 10 minutes with 360 W. Slides were cooled down to room 
temperature for 20 minutes and were then washed two times with PBS. Peroxidase 
was blocked by incubation of the slides 10 minutes in 3 % H2O2 (Merck) diluted in 
PBS and then washed again 2 x in PBS. Brain sections were blocked with MOM 
blocking solution (MOM Kit, Vector Labs)(in PBS) in a humidified chamber for 1 hour. 
Then, tissue was incubated with the primary antibody, diluted in protein concentrate 
(MOM Kit, Vector Labs) in PBST (PBS + 0,01 % Tween20 (Roth)) over night at 4°C 
  45 
in a humidified chamber. Slides were then washed 3 x 3 minutes in PBST and 
incubated 30 minutes with the second biotinylated antibody (diluted in protein 
concentrate/PBST; MOM Kit). Following, slides were 3 x 3 minutes washed with 
PBST and incubated 30 minutes with ABC solution (Vector). After wash with PBST 
and miliQ water tissue was stained with DAB (Vector). Reaction was stopped in miliQ 
water, counterstain was done with haematoxyl in (Sigma) for ~1 minute and again 
washed with miliQ water. Subsequently, brain sections were dehydrated: 
 
2 minutes in 30 % ethanol  
2 minutes in 50 % ethanol  
2 minutes in 70 % ethanol  
2 x 2 minutes in abs. ethanol  
2 x 2 minutes in xylene 
 
Tissue was embedded in Entellan mounting medium (Merck). The following day, 
dried slides were scanned and evaluated with Mirax Scan (Zeiss).  
 
1st antibodies (diluted in protein concentrate (MOM Kit, Vector)/PBST) 
· NB 300-268 (Novus Biologicals) polyclonal rabbit antibody, binding to human 
LRRK2 protein (1:300) 
· 16H7-A5 monoclonal anti-LRRK2 antibody (1:50) (AFFiRiS AG) 
· Neuron specific mouse NeuN antibody ( Millipore) (1:500) [46] 
 
2nd antibodies (1:250 diluted in protein concentrate (MOM Kit, Vector) /PBST) 
· Biotinylated anti-mouse antibody (MOM Kit, Vector)  
· Biotinylated goat anti-rabbit antibody (Vector) 
 
 
 
46 
2.2.7  RNA-Extraction from mouse tissue with RNeasy Kit 
from QUIAGEN (protocol from QUIAGEN RNeasy 
Handbook) 
 
A cube of 3mm diameter was cut out of fresh tissue and used for RNA isolation. 
Tissue-cubes were disrupted in 600 µl RLT buffer with micropistilles and 
homogenized with QUIAshredder. 600 µl of 70% ethanol was added to the 
homogenates and transferred to the RNeasy spin columns. Samples were 
centrifuged 15 seconds with 10.000 rpm, the flow-through was discarded. Then 700 
µl RW1 buffer was added and centrifuged, followed by 2 washing steps with 500 µl 
RPE buffer. After a final centrifugation of 1 minute at full speed, to dry the pellet, the 
column was placed in a fresh tube and RNA was eluted with 50 µl RNase-free water 
(1 min. at 10.000 r pm).  
 
2.2.8  Protein extraction from mouse tissue with RIPA 
buffer 
 
For protein extraction, 1ml RIPA buffer (see above) was added to the tissue, 
disruption and homogenisation was done with a glass mortar. Homogenate was then 
incubated at 4°C rotating for 30 minutes. Samples were centrifuged (4 minutes, 4°C 
with 12.000 rpm) and supernatant was transferred into a fresh tube. Samples were 
stored at -80°C until further use.  
 
2.2.9  NuPAGE Protein Electrophoresis System 
(Invitrogen) 
 
For separation of high molecular-weight proteins the NuPAGE Protein 
Electrophoresis System with 3-8 % Tris-Acetate gels (Invitrogen) was used. Western 
Blotting conditions were modified, to obtain clear separation of high molecular weight 
proteins.  
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Formulation of the NuPAGE T ris-Acetate Gels (Invitrogen)  
Precasted gel s were used 
 
NuPAGE® LDS Sample Buffer (4X) (Invitrogen) 
106 mM  Tris HCl 
141 mM  Tris base 
2%  LDS 
10%  Glycerol 
0.51 mM  EDTA 
0.22 mM  SERVA® Blue G250 
0.175 mM  Phenol Red 
pH 8.5 
 
Sample preparation for gel loading 
Sample x µl 
NuPAGE® LDS Sample Buffer (4X) 2.5 µl 
NuPAGE® Reducing Agent (10X)  1.0 µl 
Deionized Water to 6.5 µl 
 Total Volume 10 μl  
 
NuPAGE® Tris-Acetate SDS Runni ng Buffer (20X) (Invitrogen) 
50 mM  Tricine 
50 mM  Tris base 
0.1%  SDS 
pH 8.24 
 
Equal amounts of proteins for each sample were diluted in sample buffer and 
incubated at room temperature for 10 minutes until loaded on the gel. 
Electrophoresis conditions were 1 hour with 150 V.  
After separation of the sampl es in the Tris-Acetate Gel , proteins were transferred to a 
nitrocellulose membrane, as described above (transfer 1hour 30 V constant).  
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NuPAGE® Transfer Buffer (20X) (Invitrogen) 
25 mM  Bicine (Sigma) 
25 mM  Bis-Tris (free base) 
1 mM  EDTA (Sigma) 
pH 7.2 
Working solution: 
NuPAGE® Transfer Buffer (20X)  50 ml 
NuPAGE® Antioxidant 1 ml 
Methanol 200 ml 
Deionized Water 749 ml 
Total Volume 1000 ml 
 
Western Blotting and subsequent anal ysis was performed as descr ibed above.  
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3 RESULTS 
A transgenic mouse model for PD was generated and initially characterized. The 
plasmid used for transgene production carrying the human LRRK2 gene (hLRRK2), 
was cloned and tested in vitro. Subsequently transgenic hLRRK2 animals were 
tested using behavioural and biochemical methods for  LRRK2 transgene expression.  
3.1 Plasmid Characterization 
As a first step to create a novel transgenic mouse line, a full length cDNA clone 
containing the complete coding sequence of human LRRK2 was obtained from 
Origene and subsequent ly characterized.  
3.1.1  pCMV6-XL5-LRRK2 (Origene) expression analysis 
 
Before production of the transgenic mouse line transcription and translation of full 
length human LRRK2 was analyzed by testing pCMV6-XL5-hLRRK2 transfected 
cells. Then the complete CDS was cloned in pUC18-Thy1.2 (Polygene) backbone for 
transgene product ion.  
First in-vitro analysis explored expression of human LRRK2 gene inserted in the 
pCMV6-XL5 backbone (Origene) on RNA and protein level. Detection of full length 
LRRK2 RNA was done by PCR and qPCR using N-terminal and C-terminal specific 
primers. Western Blotting (WB) and immunocytochemistry (ICC) was done to detect 
LRRK2 protein in-vitro.  
 
3.1.1.1 Restriction enzyme analysis of the LRRK2 plasmid 
In order to detect LRRK2 CDS i n the pCMV6-XL5 plasmid DNA was treated with NotI 
restriction enzyme leading to cleavage on both boarders of LRRK2 gene. T he LRRK2 
insert was detected by gel electrophoresis on an agarose gel. The restriction digest 
resulted in a 4,5 kb band (pCMV6-XL5 backbone) and a 7 kb LRRK2 band (Fig.12). 
As control untreated DNA was l oaded additionally.  
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Fig.12 pCMV6-XL5-LRRK2 digestion with 
NotI enzyme. Three maxi prep samples 
treated with NotI enzyme to test LRRK2 gene 
presence. Line with ø show uncut plasmid 
DNA with 11,5kb band size. NotI treated DNA 
show LRRK2 band (7kb) and pCMV-backbone 
(4,5kb). 
 
 
In addition to this restriction digest, the LRRK2 CDS was sequenced ( Microsynth). 
Sequencing resulted in a single reading frame of 7,7 kb as expected (data not 
shown).  
 
3.1.1.2 Transcription analysis of LRRK2 plasmid 
As a second step, expression of hLRRK2 was tested in-vitro. Two different cell lines 
(CHO, HEK) were used for detection of LRRK2 RNA expression. Therefore cells 
were transfected using Lipofectamine (Invitrogen) with pCMV6-XL5-hLRRK2 vector 
(pCMV6-LRRK2) and incubated for 48 hours after transfection. Cells were disrupted 
and the protein homogenates were analysed by WB. Additionally total RNA was 
extracted with RNeasy spin columns (Quiagen) and tested by PCR/qPCR .  
RNA samples were treated with RQ1 DNase (Pr omega) to avoid DNA contami nation.  
Subsequent ly we used treated and untreated RNA for cDNA synthesis with oligo dT 
primers (Invitrogen). For evaluation of DNA contamination, cDNA synthesis was done 
in parallel without reverse transcriptase. cDNA samples were used for PCR with 
primers specific for the LRRK2 N-terminus (primer 1) and C-terminus (primer 4/5) 
and primers specific for the housekeeping gene GAPDH. H2O peripheral dopa 
decarboxylase inhibitor (benserazide or carbidopa; prevents metabolism of L-dopa) 
was also used in PCR reaction as negative control as well as plasmid DNA (pCMV6-
LRRK2) as positive control for LRRK2.  
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Analysis showed that CHO and HEK cells transfected with hLRRK2 express hLRRK2 
whereas untransfected cells do not show LRRK2 expression (Fig.13, 14). As positive 
control, GAPDH expression was detected in both transfected and untransfected cells.  
 
 
Fig.13 LRRK2 RNA detection from pCMV6-XL5-LRRK2 transfected CHO 
cells by PCR. RNA extracts from pCMV6-XL5-LRRK2 
transfected/untransfected CHO cells used for PCR with LRRK2 specific primer 
(1, 4/5) showed presence of LRRK2 RNA in transfected but not in untransfected 
cells. Primer dimers in lane 4 of left and middle gel are present. In contrast 
GAPDH specific bands can be detected in both transfected and untransfected 
CHO cells. Water control in all PCR reactions was used and loaded in lane one. 
Plasmid DNA pCMV6-LRRK2 (second lane) was used as positive control.  
-..neg. control 
 
 
 
Fig.14 LRRK2 RNA detection from pCMV6-XL5-LRRK2 transfected HEK 
cells by PCR. PCR with LRRK2 specific primer (1, 4/5) display the presence of 
LRRK2 RNA in extracts of pCMV6-LRRK2 transfected HEK cells. In contrast, 
GAPDH specific bands are detected in transfected and untransfected cell 
extracts. Water control. was loaded in the first lane. Plasmid DNA pCMV6-
LRRK2 (second lane) was used as positive control.  
-..neg. control 
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3.1.1.3 Analysis of LRRK2 expression by Western Blotting 
Protein homogenates  from transfected and untransfected CHO and HEK cell extracts 
were analysed for LRRK2 protein expression detected by Western Blotting. Total 
protein concentration was determined by Bradford assay. Thus equal amounts of 
protein were loaded and analysed by WB. Recombinant LRRK2 protein was used as 
positive control. LRRK2 (280 kD) was detected by two LRRK2 specific antibodies, 
NB300-268 and 16H7-A5, in protein extracts from transfected but not in 
untransfected cells (Fig.15). The recombinant LRRK2 protein with 205 kD was also 
detected by both antibodies.  
 
 
3.1.1.4 Fluorescence-immunocytochemistry (FICC) and Immunocytochemistry 
(ICC) of pCMV6-LRRK2 transfected cells 
The presence of LRRK2 protein in WB prompted us to determine the cellular 
localization of LRRK2 by FICC/ICC. Therefore CHO and HEK cells were transfected 
with pEGFP (plasmid expressing green fluorescent protein), as transfection control, 
and pCMV6-LRRK2. As showed in Fig.16 and 17 LRRK2 protein expression was 
detected by NB300-268 antibody (Novus Biologicals). We observed structured 
cytoplasmic localization of LRRK2 protein only in transfected CHO and HEK cells 
(red). GFP was also detected in the cytosol (green). Nuclear staining was done with 
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Fig.15 Western Blotting with cell culture protein extracts. pCMV6-XL5-LRRK2 
transfected cells tested for expression of LRRK2 protein by LRRK2 specific antibodies 
NB300-268 and 16H7-A5. NB300-268 showed a band with the expected size of LRRK2 
protein (~280 kD) in transfected but not in untransfected cells. Rec. LRRK2 protein was 
used as control for Western Blotting with a size of ~205 kD leading to different migration 
of rec. and endogenous LRRK2 protein. 16H7-A5 antibody also detects LRRK2 protein in 
transfected but not in untransfected cells.  
green cycle...rec. LRRK2 protein  
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DAPI mounting medium (blue fluorescent), Vector) or haematoxyl in (blue). 
Additionally LRRK2 shows punctuate staining pattern in transfected cells. These 
results were expected as Hatano et al [37] could show that LRRK2 pr otein associates 
with lipid rafts, early endosomes, mitochondrial membrane, lysosomes, synaptic 
vesicles, cytoskeleton, golgi apparatus and the endoplasmic reticulum. Unspecific 
binding of NB300-268 or secondary antibody was not detected in untransfected cells 
or staining with secondary antibody only.  
 
 
Fig.16 Immunocytochemistry with CHO cells transfected/untransfected with pCMV6-XL5-LRRK2. (A-C) 
DAB staining with biotinylated secondary antibody, (D-F) fluorescence immunocytochemistry (FICC) with texas 
red conjugated secondary antibody. (A) Untransfected CHO cells stained with LRRK2 specific antibody NB300-
268 show no background signal of staining. (B) pCMV-LRRK2 transfected CHO cells incubated with biotinylated 
secondary antibody alone do not show unspecific binding of the antibody. (C) LRRK2 protein staining in pCMV-
LRRK2 transfected CHO cells with NB300-268 indicating cytoplasmic localisation of the protein. (D) FICC with 
pEGFP transfected CHO cells show GFP expression but fail to show NB 300-268 signals. (E) pCMV-LRRK2 
transfected CHO cells incubated with secondary antibody alone does not indicate unspecific binding. (F) 
Cytoplasmic localisation of LRRK2 protein in pCMV-LRRK2 transfected CHO cells (red). 
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Fig.17 Immunocytochemistry with HEK cells transfected/untransfected with pCMV6-XL5-LRRK2. (A, B) ICC 
(C) FICC. (A) Untransfected HEK cells stained for background detection show no signal. (B) pCMV6-LRRK2 
HEK cells stained with NB300-268 antibody detect LRRK2 protein in the cytoplasm. (C) Similar staining was 
obtained with FICC. 
 
Summarizing LRRK2 RNA was detected in CHO and HEK derived RNA extracts by 
PCR. Also by WB and immunocytochemistry LRRK2 protein could be detected in cell 
extracts.  
Plasmid DNA was sent to Pol ygene for transgene production. 
 
3.1.2  pUC18-Thy1.2-LRRK2 (Polygene) expression 
analysis 
 
In order to generate a novel transgenic mouse over-expressing hLRRK2 in neurons, 
the hLRRK2 cDNA was cloned into a pUC18 vector containing the neuron specific 
Thy1.2 promoter cassette. Cloning was performed at Polygene. After successful 
cloning, the insert was verified by DNA sequenci ng.  
The pUC18-Thy1.2-hLRRK2 plasmid was injected into zygotes and transferred into 
IVC-held foster mothers. For in-vitro analysis of pUC18-Thy1.2-hLRRK2 expression, 
Polygene delivered plasmid DNA to AFFiRiS AG. 
The new plasmid pUC18-Thy1.2-hLRRK2 (Thy1.2-LRRK2) was checked for LRRK2 
expression. Therefore LRRK2 RNA was detected by PCR and LRRK2 protein by WB 
and FICC/ICC, as shown for pCMV6-XL5-LRRK2 plasmid.  
 
3.1.2.1 Restriction enzyme digestion 
Determination of human LRRK2 CDS in the Thy1.2-LRRK2 vector was done by 
restriction enzyme digestion. Plasmid DNA was cut with PvuI, XhoI, EcoRV, EcoRI or 
HindIII enzymes to get different cleavage fragments, which were separated by gel 
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electrophoresis for evaluation. As expected PvuI produced 2 fragments, XhoI cut 
once leading to one fragment, EcoRV produced 3 fragments, EcoRI produced 5 
fragments and HindIII 5 fragments (Fig.18).  
This analysis confirmed correct insertion of the hLRRK2 sequence into pUC18-
Thy1.2 plasmid.  
 
Enzyme Fragments Fragment size in kb 
Pvu I 2 16, 1 
Xho I 1 17 
EcoR V 3 12, 3, 2 
EcoR I 5 6, 5, 3.4, 2.2, 0.24 
Hind III 5 9, 4.5, 1.7, 1.5, 0.3 
 
 
Fig.18 Restriction enzyme treatment of pUC18-Thy1.2-LRRK2. First two 
lanes show DNA ladder high and low range (Fermentas). Pvu I enzyme led to 
16 kb and 1 kb fragments. Xho I cut once in the vector leading to 17 kb band. 
EcoR V produced 12 kb, 3 kbp and 2 kb. EcoR I led to 6 kb, 5 kb, 3.4 kb, 2.2 
kb, and 0,24 kb fragments. Enzyme Hind III produced 5 DNA brands with the 
size of 9 kb, 4.5 kb, 1.7 kb, 1.5 kb and 0,3 kb. Short fragments were detected 
because of long separation time. Restriction enzyme treatment showed the 
presence of LRRK2 in the plasmid.  
 
3.1.2.2 Reverse transcription and qPCR 
Detection of LRRK2 RNA expressed from the pUC18-Thy1.2 plasmid, was done by 
quantitative PCR (qPCR) using LRRK2 specific primers in different transfected cell 
lines. An internal control ( ribosomal protein L32) was used as reference.  
Two different cell lines, HEK and SH-SY5Y were used for expression analysis by 
qPCR.  
As described above, RNA samples were treated with RQ1 DNase (Promega) to 
avoid DNA contamination and tested for DNA contamination. For qPCR LRRK2 
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specific primers (primer 1) and housekeeping gene primers were used (Rpl32 primer 
1).  
Amplification of primer targets is illustrated by increasing fluorescence signal in 
Fig.19.A. After PCR reaction, the specificity of the primers was controlled by 
measurement of a single melting peak for each primer pair (Fig.19.B). The table 
shows the numbers of cycles when fluorescence threshold is reached. The lower the 
number of cycles the more template DNA is present at the beginning of the PCR 
reaction. Samples were used in duplicates and the average calculated. Values from 
samples without reverse transcriptase (-RT; background signal) were subtracted to 
get an approximate estimation of RNA expression.  
Analysis confirmed expression of LRRK2 RNA in transfected HEK cells but not in 
SH-SY5Y cells. As expected Rpl32 expression was detected in all cell lines 
(Fig.19.C).  
 
 
Fig.19 qPCR with cDNA from different cell lines transfected with pUC18-Thy1.2-LRRK2. qPCR reaction 
graph from two primer pairs, showing increasing fluorescence signal with progressing cycle number (A). The 
melting peak chart shows melting points of the fragments after PCR reaction. One temperature maximum for 
each primer indicates amplification of a single target sequence (B). Table of results illustrates the presence of 
LRRK2 cDNA in HEK cells indicated by the red circle (C). 
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Samples obtained from qPCR were additionally analysed by gel electrophoresis 
(Fig.20). Results showed the expected bands for both primer pairs. Unspecific 
amplification was not detected. Rpl32 bands showed similar results as obtained by 
qPCR, indicating expression in all cells. LRRK2 bands in SH-SY5Y samples without 
reverse transcriptase (- SS II RT) display plasmid DNA contamination. This 
contamination did not exist in HEK cell samples. Therefore LRRK2 RNA expression 
was detected  in transfected HEK cell s, supporting the qPCR results.  
 
 
Fig.20 qPCR gel from different Thy1.2-LRRK2 transfected cell lines to detect 
LRRK2 RNA expression. Left picture indicates cDNA from Rpl32 house-keeping 
gene in different Thy1.2-LRRK2 transfected cell lines. Signal in lines with plus are 
from reverse transcription and contain cDNA (+ SS II RT); in lines with minus there 
is no signal because of absence of reverse transcription (- SS II RT) to exclude the 
contamination with plasmid DNA. Right picture shows LRRK2 specific bands, in 
SH-SY5Y samples the signals (in minus lanes) indicate plasmid DNA 
contamination. Only in HEK samples contamination can be excluded, bands are 
LRRK2 cDNA specific. 
 
 
In addition LRRK2 RNA expression from pCMV6-LRRK2 and Thy1.2-LRRK2 
plasmids was compared in HEK cells following transfection. pCMV6-LRRK2 
transfection efficiency was much higher compared to plasmid Thy1.2-LRRK2, 
therefore providing a positive control for further analysis. Again qPCR was used to 
assess Rpl32 and LRRK2 cDNA, synthesi zed from total cell RNA extracts (Fig. 21).  
 
58 
 
Fig.21 qPCR with RNA from pCMV-LRRK2 or 
Thy1.2-LRRK2 transfected HEK cells. LRRK2 RNA 
expression from two different plasmids was tested by 
qPCR. Rpl32 primer for house keeping gene should be 
equally expressed in all cells which was not the case 
for HEK-pCMV-LRRK2/HEK cells (diff. +RT 4,3) 
indicating different template concentrations. This 
difference must be considered, leading to 4,76 cycles 
difference of LRRK2 RNA between pCMV-LRRK2 
transfected and untransfected cells. LRRK2 RNA 
expression was detected in HEK Thy1.2-LRRK2 
transfected cells (1,69).  
 
As shown in Fig.21 Rpl32 gene expression was present in all samples tested (middle 
lane). Unexpectedly, Rpl32 expression was not equal in pCMV6-LRRK2 transfected 
and untransfected HEK cells indicated by 4,3 PCR cycles difference. LRRK2 RNA 
expression was detected in pCMV6-LRRK2 and Thy1.2-LRRK2 transfected HEK 
cells. pCMV6-LRRK2 transfected HEK cells showed higher LRRK2 RNA levels (4,76 
PCR cycles difference in pCMV6-LRRK2 transfected HEK cells compared to 1,69 
cycles in Thy1.2-LRRK2 transfected cells). Thus, pCMV6-LRRK2 transfection 
efficiency seems to be much higher compared to plasmid Thy1.2-LRRK2. 
Again qPCR samples were loaded on an agarose gel (Fig.22). Obtained bands 
showed the correct size and specificity of the primers. Empty Rpl32 primer minus 
lanes indicated absence of genomic DNA contamination. In HEK pCMV6-LRRK2 
cells plasmid DNA contamination was present, which was not the case in Thy1.2-
LRRK2 transfected cells (no band in lanes without reverse transcriptase; - SS II RT). 
Thus, the DNase treatment was not sufficient to remove all DNA from the HEK 
pCMV6-LRRK2 samples.  
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Fig.22 qPCR samples separated on a gel. 
Upper picture shows expression of Rpl32 
RNA in both cell samples but only in + SS II 
RT lane on the left side, indicating absence 
of gDNA contamination. Right side shows 
pCMV-LRRK2 contamination in – SS II RT 
lane and a weak signal in untransfected HEK 
cells. High intensity of positive signal 
indicated presence of LRRK2 RNA in pCMV-
LRRK2 transfected HEK cells. Rpl32 bands 
in the lower picture indicate absence of 
gDNA contamination. LRRK2 RNA could 
only be detected in Thy1.2-LRRK2 
transfected HEK cells.  
 
As expected from qPCR, LRRK2 expression was confirmed. In Thy1.2-LRRK2 
transfected HEK cells a signal solely derived from LRRK2 RNA was obtained. In 
contrast in pCMV6-LRRK2 transfected HEK cells the signal was contaminated by 
plasmid DNA. Nevertheless, the stronger gel band in HEK pCMV6-LRRK2 +RT lanes 
compared to –RT lanes indicated LRRK2 RNA expr ession.  
Overall, LRRK2 expression was detected from both plasmids.  
 
3.1.2.3 Analysis of LRRK2 expression by Western Blotting 
As mentioned above, proteins from transfected and untransfected HEK cell extracts 
were analysed for the presence of LRRK2 by SDS Page and WB. Blots were 
incubated with three different LRRK2 specific antibodies (NB300-268, AB 9682 and 
16H7-A5) to detect protein expression (Fig.23). As positive control additionally 
recombinant LRRK2 pr otein was loaded on the gel.  
NB300-268 antibody detected rec. LRRK2 protein and a weak LRRK2 protein band 
in HEK Thy1.2-LRRK2 cell extracts, but not in untransfected HEK cells. Recent 
results showed an increased cell death induced by the Thy1.2-LRRK2 plasmid, 
making analysis difficult (C.Lahsnig, pers. communication). In addition unspecific 
bands were detected as well .  
Antibody AB 9682 failed to detect rec. LRRK2 protein (pos. control) and showed only 
weak unspeci fic binding.  
Monoclonal antibody 16H7-A5 recognized rec. LRRK2 protein only, but proteins from 
cell extracts were not detected.  
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Fig.23 Western blot with HEK protein extracts. In the left panel recombinant LRRK2 
protein (~ 205 kD) was detected. A weak signal of LRRK2 protein (~280 kD) was detected 
in HEK cells, showing a small difference in band intensity between transfected and 
untransfected HEK cells. In the middle, AB 9682 failed to detect rec. LRRK2 protein and 
over-expressed LRRK2. Similar results to AB 9682 were achieved by 16H7-A5, though rec. 
LRRK2 protein was detected (right panel). 
 
Additionally, LRRK2 expression was tested in Thy1.2-LRRK2 transfected and 
differentiated SH-SY5Y cells (differentiation has been done usi ng retinoic acid).  
NB300-268 and 16H7-A5 antibody incubation resulted in highly unspecific signals, 
therefore LRRK2 expression could not be determined (data not shown) .  
 
3.1.2.4 Fluorescence-immunocytochemistry (FICC) and Immunocytochemistry 
(ICC) of Thy1.2-LRRK2 transfected cells 
The presence of LRRK2 protein in WB prompted us to determine the cellular 
localization of LRRK2 by FICC/ICC in CHO and SH-SY5Y cells. Cells were 
transfected with Thy1.2-LRRK2 vector. The NB300-268 antibody specific for LRRK2 
was used. Protein detection was done by DAB or fluorescence staining.  
Staining of CHO cells transfected with Thy1.2-LRRK2 failed to show LRRK2 specific 
signal with DAB staining (Fig.24). Fluorescence staining revealed a signal indicative 
of LRRK2 expression.  
In addition, SH-SY5Y cells transfected wi th both plasmids were stained using NB300-
268 antibody. Cytoplasmic staining was detected but there was no difference in the 
staining pattern of transfected and untransfected cells (data not shown) .  
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LRRK2 expression was detected in cells transfected with pUC18-Thy1.2-LRRK2 
plasmid by PCR and qPCR. LRRK2 protein was only weakly detected in transfected 
HEK cells by WB and in CHO cells by FICC. In other cell lines LRRK2 protein 
expression could not be demonstrated. Again this might be due to the increased 
apoptosis detected in the presence of Thy1.2-hLRRk2 leading to a very low number 
of hLRRK2 posi tive cells (C.Lahsnig, per s. communication). 
 
 
Fig.24 Immunocytochemistry with CHO cells transfected with Thy1.2-LRRK2. (A) Thy1.2-LRRK2 
transfected CHO cells stained with NB300-268 antibody failed to show LRRK2 specific staining. (B) 
FICC staining with these cells incubated by the same antibody detected LRRK2 protein in the cytoplasm. 
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3.2 Characterization of LRRK2 transgenic 
founder animals 
 
Transgenic animals were generated and bred by PolyGene according to 
standardized methods. Transgenic animals were genotyped and analysed by 
behavioural tests and biochemical analysis. 
 
3.2.1  Genotyping 
 
Breeding cages with transgenic (tg) animals and wild-type littermates (wt; C57Bl/6N) 
of four months of age were delivered to AFFiRiS AG. First, presence of the LRRK2 
transgene was detected by genotyping PCR. The number of inserts in the genome 
was determined by semi-quantitative PCR and qPCR. Subsequent ly, characterization 
of founders including observation of normal animal behaviour was initiated. Wt as 
well as tg mice were showing no di fferences in normal behaviour. 
 
3.2.1.1 Genotyping PCR 
For genotyping, genomic DNA (gDNA) was used with human LRRK2 specific primers 
1 and 4/5 for transgene detection and mouse specifc GAPDH primers as positive 
control (housekeeping gene primer) (Fig.25). H2O was used as negative control 
(minus), Thy1.2-LRRK2 plasmid DNA as posi tive control (plus).  
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Fig.25 Genotyping PCR with founder DNA. House-keeping gene specific primer 
mGAPDH shows specific bands in all animals. LRRK2 specific primer 1 and 4/5 indicate 
transgenic animals 3,4,6 and 11 leading to 4 different founder lines (in red). Water as neg. 
control (minus) and Thy1.2-LRRK2 plasmid DNA as pos. control (plus).  
 
After PCR, samples were separated by agarose gel electrophoresis. As expected, 
results from genotyping PCR reproduced the data from Polygene (four transgenic 
animals (4 lines) and corresponding wt animals). The negative control showed no 
PCR signal, positive control displayed the same band as in transgenic mouse 
samples. Taken together three male and one female founder (li ne 2) was obtained.  
 
3.2.1.2 Semi-quantitative PCR 
After genotyping, the relative number of LRRK2 insertions in the tg founder animals 
was determined. Therefore semi-quantitative PCR (sqPCR) was done with gDNA 
from the four founder animals. As a  positive PCR control, control gene primers 
(mGAPDH) were used and LRRK2 primers for transgene detection. PCR reaction 
was stopped after 16, 18, 21, 24, 27, 30, 33 and 36 cycles and loaded on an agarose 
gel (Fig.17).  
Amplicon size from both primers showed in all lines the expected results. The bands 
obtained using GAPDH primers lead to similar intensity of the signal in all animals 
and correlated to the respective LRRK2 signals. The ratio indicates the amount of 
transgene as compared to the housekeeping gene. According to the results 
displayed in Fig.26, lane 2 showed the lowest sqPCR signal, however results did not 
allow to determine whether line 1,3 and 4 show higher copy numbers. Thus qPCR 
was performed as well.  
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Fig.26 sqPCR with founder DNA. Determination of LRRK2 
integration number with sqPCR using house-keeping gene primer 
and LRRK2 primer. Samples were stopped after different reaction 
cycles (16, 18, 21, 24, 27, 30, 33 and 36 cycles) and loaded on a gel 
from left to right. The number of LRRK2 gene integrations in the 
genome starting with the highest is line 3 > 1 > 4 > 2. 
 
3.2.1.3 Quantitative PCR (qPCR) 
Results from semi-quanti tative PCR were confirmed by qPCR. The signal obtained 
from the amplification of the IL2 gene with two copies in the genome was compared 
to the transgene signal (hLRRK2; LRRK2 primers 1). The amount of LRRK2 
integrations in the genome was determined subsequent ly. In this analysis the tg 
founder gDNA was included. According to Fig.27.A, LRRK2 reaches threshold earlier 
than IL2. Therefore more LRRK2 insertions than IL2 are present in the genome. 
Results from melting peak determination confirmed specificity of both primers 
(Fig.27.B).  
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Fig.27 qPCR with founder genomic DNA. Determination of transgene integration number in the genome of 
founder animals by RT-PCR using IL2 primer and LRRK2 primer. An illustration of RT-PCR cycles is shown on 
the left side (LRRK2 signal…red arrow, IL2 signal…blue arrow). Melt curve of PCR samples after PCR reaction is 
shown on the right side, indicating the purity of the amplicon. 
 
 
After data analysis we calculated the approximate integration number of LRRK2 in 
the genome of founder  animals compared to the IL2 gene (two copies per genome).  
Results showed the highest LRRK2 integration number in the genome of the animal 
in line 3, followed by line 1 and 4. The lowest number was detected i n line 1 (Fig.28). 
These results were consistent with the results obtained by semi-quantitative PCR.  
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Fig.28 qPCR with LRRK2 founder DNA. LRRK2 integrations in the genome 
show the highest number in line 3 followed by line 1 and 4. The lowest copy is 
present in line 2.  
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3.3 Initial characterization of the 4 tg lines 
 
Founder animals and the offspring from four different lines were analysed by PCR to 
check their genotype for further breeding (Fig.25, 29, 30). Progenies of line 3 and 4 
were analysed starting with two months of age.  
 
3.3.1  Genotyping PCR of transgenic LRRK2 mice 
 
Tail biopsies from offspring of all four lines (animal 12-34), were used for genotyping 
PCR. LRRK2 specific primers 1 and 4/5 were used for transgene detection, 
mGAPDH primers as positive controls. Thy1.2-LRRK2 DNA was used as positive 
control (plus) and H2O for detection of contamination (minus). After PCR, samples 
were separated by gel  electrophoresis (Fig.30).  
According to Fig.20, GAPDH was detected in all animals except of animal 30. The 
Transgene specific signal was detected in 5 out of 23 pups (animal 13, 21, 23, 33 
and 34) (red arrow). Positive control was detected with all primers and the water 
control showed no signal. The transgenic animals obtained were used together with 
wild type littermates for further behavioural and biochemical analysis to detect 
transgene expression.  
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No. sex  date of birth genotype Line animal status
1 f 28.07.2008 wt 1 founder
2 f 28.07.2008 wt 1 founder
3 m 28.07.2008 tg 1 founder
4 f 28.07.2008 tg 2 founder
5 m 28.07.2008 wt 2 founder
6 m 28.07.2008 tg 3 founder
7 f 28.07.2008 wt 3 founder
8 f 28.07.2008 wt 3 founder
9 f 28.07.2008 wt 4 founder
10 f 28.07.2008 wt 4 founder
11 m 28.07.2008 tg 4 founder
12 m 25.11.2008 wt 3 offspring
13 f 25.11.2008 tg 3 offspring
14 f 25.11.2008 wt 3 offspring
15 f 25.11.2008 wt 3 offspring
16 f 27.11.2008 wt 1 offspring
17 f 27.11.2008 wt 1 offspring
18 m 27.11.2008 wt 1 offspring
19 m 27.11.2008 wt 1 offspring
20 m 27.11.2008 wt 1 offspring
21 m 25.11.2008 tg 4 offspring
22 f 25.11.2008 wt 4 offspring
23 f 05.12.2008 tg 4 offspring
24 f 05.12.2008 wt 4 offspring
25 f 07.12.2008 wt 1 offspring
26 f 07.12.2008 wt 1 offspring
27 f 07.12.2008 wt 1 offspring
28 m 07.12.2008 wt 1 offspring
29 m 07.12.2008 wt 1 offspring
30 m 07.12.2008 wt 1 offspring
31 m 07.12.2008 wt 1 offspring
32 f 19.12.2008 wt 4 offspring
33 f 19.12.2008 tg 4 offspring
34 f 19.12.2008 tg 4 offspring
LRRK2 animals
 
Fig.29 Table of LRRK2 mice, including founder (1-11) and offspring 
(12-34). m...male, f...female, wt...wild-type, tg...transgene 
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Fig.30 Genotyping PCR with pups DNA. GAPDH specific house-keeping bands were detected in all animals 
except animal 30 where genomic DNA was absent. Signals with LRRK2 specific primer lead to 5 transgenic 
animals (13, 21, 23, 33 and 34) out of 23 pups (red arrow). 
 
3.3.2  Genotyping qPCR of transgenic LRRK2 mice 
 
Consequent ly we were interested in the number of transgene integrations in the 
genome of the offspring  and compared it to founder animals.  
Therefore qPCR was performed with gDNA from founder  animal (11, line 4) and pups 
(13, line 3 and animal 23, line 4) with IL2 specific primers and a LRRK2 specific 
primer pair (primers 1). Results showed that line 3 had again the highest integration 
number followed by line 4 as obtai ned before (data not shown) .  
 
In order to characterize the phenotype of the lines 3 and 4, 6 animals were chosen (4 
from line 4 and 2 f rom line 3). Two animals (male tg animal 23, wt animal 24 from line 
4) with two months of age were chosen for behavioural and biochemical analysis. 
Two months later four animals were analysed with four months of age (male tg 
animal 12 and wt animal 21 from line 4, female tg animal 13 and wt animal 14 from 
line 3).  
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3.3.3  Analysis of the motor function from transgenic 
LRRK2 mice 
 
The motor function of six animals was monitored by different tests. At the first day of 
training, the grooming behaviour of the animals was observed and no difference in 
behaviour between wt and tg  was detected .  
Beam, pole and grid test were performed as described in section 2 (Material and 
Methods).  
After data collection and comparison (Fig.31) we did not detect any difference in 
behaviour between wt and tg animal, probably due to the low number of animals 
tested.  
Subsequent ly animals were sacrificed for biochemical analysis of transgene 
expression.  
 
line sex U-turn time run time
23 4 m 2 tg n.d. 2,2 7,4 91
24 4 m 2 wt n.d. 2,7 10,3 106
12 4 m 4 wt 0,4 4,2 5,2 118
21 4 m 4 tg 0,3 2,2 13,3 120
13 3 f 4 tg 0,2 2,9 5,7 120
14 3 f 4 wt 0,2 2,3 4,8 120
animal genotype
Test
pole (sec.)
grid (sec.)
beam 
(errors/step)
age 
(month
 
Fig.31 Summary of behavioural tests. LRRK2 offspring (12, 21, 13, 14, 23 and 24) tested by beam, pole and 
grid test.  
 
As shown before the biochemical analysis of transgene expression was started with 
male pups 23 and 24 (two months of age, line 4). Furthermore, the effects of the high 
integration number in line 3 on transgene expression was tested and compared to 
effects obtained from analysis of animals from line 4. Therefore female tg animal 13 
and wt animal 14 from line 3 with four months of age were chosen. Transgene 
expression was also tested in four month old male animals 12 and 21 from line 4.  
LRRK2 RNA was detected by PCR and qPCR, LRRK2 protein by Western Blotting 
and IHC.  
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3.3.4  Tissue RNA extraction and PCR/qPCR of transgenic 
mice 
 
Mice were sacrificed and RNA was extracted from different tissues (brain, gut, heart 
liver, lung, stomach, spleen, muscle, kidney and spinal cord) to test LRRK2 RNA and 
protein expression.  
 
The extracted RNA not treated with DNase I was leading to specific LRRK2 bands in 
nearly all tissues of tg animal (see Fig.32). LRRK2 signals were specific because the 
wt animal displayed no LRRK2 signal in any tissue. Instead, PCR using mGAPDH 
primers lead to bands in all tissues. As positive control Thy1.2-LRRK2 plasmid DNA 
was used and water  as negative control.  
 
 
Fig.32 PCR with animal 23 and animal 24 tissue cDNA (not treated with DNase I). mGAPDH primer for 
house keeping gene gave positive bands in every tissue of both animals. LRRK2 specific primers gave signals 
only in transgenic animal 23 in all tissues except of heart and muscle. 
 
Female animals wt 13 and tg 14 from line 3 (four months old) were also tested for 
LRRK2 RNA expression by PCR and qPCR. Results in Fig.33 show Rpl32 RNA 
expression in all tissues analysed. LRRK2 RNA could only be detected in the tg 
animal and was restricted to the brain and spinal cord. gDNA contamination was not 
detectable as indicated by the absence of a signal in samples without reverse 
transcriptase (-RT).  
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Fig.33 PCR with cDNA from 13 (tg) and 14 (wt) tissue RNA. Rpl32 primer shows similar results in tissues of 
both animals. LRRK2 cDNA is only present in L13 brain and spinal cord, it could not be detected in other tissues 
of this animal or in the wild type. red circle … LRRK2 RNA band, sp.c. ..spinal cord, RT … reverse transcriptase 
 
 
Results from qPCR (Fig.34) with RNA from brain, spinal cord and lung (negative 
control) show expected results. Rpl32 RNA was detected in all tissues, LRRK2 RNA 
was only detected in brain and spinal cord. Signal from lung indicated presence of 
unspecific amplification or primer dimerisation. According to Fig.34.A, Rpl32 signal 
reaches threshold earlier than LRRK2. Results from melting peak determination 
confirmed specificity of both amplicons (Fig.34.B).  
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Fig.34 qPCR with cDNA from 13 (tg) brain, spinal cord and lung. (A) Illustration of PCR. (B) Melt curve peaks for 
amplicon purity determination. (C) Results of qPCR show LRRK2 RNA expression in brain and spinal cord (red 
circles), results from lung were not counted as LRRK2 RNA expression due to high cycle numbers (Ct value) 
indicating background signal.  
 
Samples from qPCR were also separated by electrophoresis (Fig.35). As expected, 
qPCR showed absence of DNA contamination (no bands in –RT lanes) and LRRK2 
RNA presence in brain and spinal cord of the tg animal 21.  
 
 
Fig.35 Gel electrophoresis of qPCR samples. PCR with Rpl32 primer showed bands in every tissue. LRRK2 
specific primers show RNA expression in brain and spinal cord, but not in the lung. Signals from cDNA and not 
genomic DNA contamination because samples without reverse transcriptase (SS II RT) do not show any signal.  
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LRRK2 RNA expression was also tested in four month old male animals from line 4 
and compared to two month old animals 23 and 24 (above). Transgenic animal 21 
and wt animal 12 were used for PCR and qPCR analysis. Fig.36 showed Rpl32 
expression in all tissues, LRRK2 RNA was also present in all tissues except for the 
spleen thus reproducing the expression profile obtained before.  
 
 
Fig.36 Gel electrophoresis of qPCR samples from animal 21 (tg) cDNA. Rpl32 signal is present in 
every tissue as positive control for qPCR reaction. LRRK2 cDNA is present in every tissue except of 
spleen. Samples without reverse transcription show no signal indicating the absence of genomic DNA 
contamination. 
 
 
Results from qPCR showed the highest LRRK2 RNA expression in the brain, 
followed by decreasing amounts of LRRK2 RNA in the spinal cord, lung, heart, 
stomach, liver and gut (data not shown). In the spleen LRRK2 RNA was not 
detected, Rpl32 was detected  in all tissues.  
 
3.3.5  Western Blotting of tissue homogenates 
 
For Western Blotting, remaining tissue from RNA extraction was used for protein 
extraction with RIPA buffer. The protein concentration of the homogenates was 
determined by Bradford measurement (data not shown) and equal amounts were 
analysed by WB. For the analysis of protein samples from animals 23 and 24, two 
different amounts of homogenates were loaded due to the low detection limit of the 
LRRK2 antibody compared to control antibodies (tyrosine hydroxylase TH, ß-actin). 
As additional loading control truncated rec. LRRK2 protein was loaded (205 kD, aa 
970-2527, Invitrogen) as well as a cell extract from pCMV6-LRRK2 transfected CHO 
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cells. After transfer, the membrane was cut into three pieces. For LRRK2 detection a 
monoclonal LRRK2 specific antibody (16H7-A5) or the polyclonal NB300-268 
antibody was used. The anti-TH antibody (60 kD) and anti-ß actin antibody (41 kD) 
were used as loading controls.  
Animals 23 and 24 from line 4 were analysed on WB for LRRK2 expression. 16H7-
A5 antibody detected recombinant LRRK2 protein and LRRK2 protein in cell extracts 
as well as in brain homogenates at the expected size (Fig.37). Although the wt 
animal also showed a faint signal at the expected size LRRK2 expression seemed to 
be increased in tg brain samples as compared to the wt brain. The detection LRRK2 
in the non-transgenic animal indicates, that 16H7 -A5 is not only binding to human but 
also mouse LRRK2 protein in WB. Loading control signal from anti-TH and anti-ß 
actin staining displayed equal  loading (1 µl homogenate was l oaded into each lane).  
 
1 → rec. LRRK2 protein (~205 kD)
2 → CHO pCMV-LRRK2 ( ~280 kD)
3 → L23 brain homogenate (tg)
4 → L24 brain homogenate (wt)
1 2 3 4
16H7-A5
anti- ß-actin
anti-TH
LRRK2
rec. LRRK2
 
Fig.37 Western Blotting with brain protein homogenates from animal 23 (tg, lane 3) and animal 24 
(wt, lane 4) animals. Lane 1 loaded with recombinant LRRK2 protein (~205 kD), lane 2 loaded with CHO 
pCMV6-LRRK2 cell extracts. Lane 3 was loaded with tg brain (23) and lane 4 with wt homogenates (24). 
Membranes were incubated with LRRK2 antibody 16H7-A5 and two loading control antibodies, the anti-
tyrosine hydroxylase (60 kD) and anti-ß actin (41 kD). Both loading control antibodies showed equal loading 
of brain homogenates. 16H7-A5 antibody showed a signal with expected size of LRRK2 protein (~280 kD, 
red arrow) in CHO cell extracts and brain samples. Additionally rec. LRRK2 protein was detected (green 
arrow). The signal of LRRK2 protein was stronger in the transgenic animal than in the wild type. 
 
3.3.6  Immunohistochemistry (IHC) 
 
In order to analyse expression of hLRRK2 in the brain of tg animals, brain 
hemispheres of animals 23, 24, 12, 21, 13 and 14 were sectioned and subsequent ly 
stained with the antibodies NB300-268 and 16H7-A5.  
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Slides were also incubated with secondary antibody only, to indicate unspecific 
binding. Staining was documented using a Mirax Scan (Zeiss). Brain regions 
analysed include brainstem, medulla and midbrain.  
Fig.38 shows IHC with brain sections from animal 23 and 24 (line 4). Negative 
controls using anti-mouse secondary antibody showed weak background only in 
contrast to anti-rabbit secondary antibody. NB300-268 (rabbit polyclonal antibody) 
staining showed a high background signal. An overall strong staining in tg as 
compared to wt littermates was detectable but the background does not allow to 
define expression on a cellular level. Incubation with 16H7-A5 antibody showed no 
difference between tg  (23) and wt (24).  
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Fig.38 IHC with animal 23 (tg) and 24 (wt) brain sections. Midbrain region from tg and wt animal are displayed 
in parallel. Background signal with biot. anti-mouse secondary antibody is present (A,E). No detection of 
background signal with biot. anti-rabbit antibody (B,F). 16H7-A5 incubation (C,G) displayed no difference 
between wt and tg compared to NB300-268 (D,H). cb… cerebellum, bs… brainstem, c… cortex, a… anterior, p… 
posterior, d… dorsal, v… ventral 
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IHC with brain sections from other animals (12, 21, 13 and 14) showed similar 
results.  
Strong signals on NB300-268 stained sections could indicate LRRK2 expression in 
the brain not only specific for human but also for mouse LRRK2 protein. Thus the 
antibody tested does not allow determination of hLRRK2 expression due to potential 
detectiuon of both mouse and human LRRK2 as wel l because of high background. 
 
Fig.39 shows LRRK2 localization on the cellular level comparing the expression 
patterns obtained by two different antibodies. The mouse monoclonal antibody 16H7-
A5 showed stronger LRRK2 stai ning intensity in wt than in tg again indicating that the 
specificity is not limited to human LRRK2 (as shown in WB). Similar staining patterns 
in wt and tg was achieved by NB300-268. Concluding, this analysis provides 
evidence that mLRRK2/hLRRK2 protein is localized in the cytoplasm as already 
indicated by the in-vitro analysis (ICC of LRRK2 over -expressing cells).  
 
Fig.39 Immunocytochemistry of 12 (wt A, B) and 21 (tg C, D) mice on cellular level (brainstem). Left 
pictures show staining with 16H7-A5 antibody specific for LRRK2 protein in wt and tg animal. In the wt (A), a 
stronger cytoplasm staining with 16H7-A5 was detected than in the tg animal (C). NB300-268 staining (B, D) 
shows similar signals in wt (B) and tg (D) animal. (scale indicates 50 µm) 
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Animal Line NB300-268 16H7-A5 
23 4 (tg) + (unspecific) - 
24 4 (wt) +/- (unspecific) + 
12 4 (wt) + (unspecific) + 
21 4 (tg) + (unspecific) - 
13 3 (tg) + (unspecific) - 
14 3 (wt) + (unspecific) - 
 
Fig.40 IHC results. Summary of IHC results from tested brain sections. Offspring 23, 24, 
12, 21, 13 and 14 were analysed. Antibody NB300-268 and 16H7-A5 were used for 
LRRK2 detection.  
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4 DISCUSSION 
The aim of this diploma thesis was the initial characterization of a novel transgenic 
mouse line over-expressing hLRRK2 under the control of a neuron specific promoter. 
This mouse line will be used to elucidate the role of LRRK2 in the nervous system in 
vivo and might thus shed light on the role of LRRK2/Dardarin/PARK8 in the etiology 
of PD and related disorders.  A thorough analysis of LRRK2 function by over-
expression of wt LRRK2 could also be instrumental to evaluate whether LRRK2 is a 
potential target for the development of novel treatment strategies against Parkinson’s 
disease and related neurodegenerative diseases in the future.  
 
As a first step before tg production the vector containing full length hLRRK2 cDNA 
was tested. In-vitro expression analysis of pCMV6-XL5-LRRK2 plasmid was done by 
PCR and qPCR. Beside full length mRNA, LRRK2 protein was also detected by 
Western Blotting and FICC/ICC. The hLRRK2 cDNA insert was subsequentl y cloned 
into the pUC18-Thy1.2 vector [42], which was used for transgene production. The 
mouse Thy1.2 expression cassette as used in the design of the transgene described 
in this thesis is well known to induce expression of the transgene in neurons in 
peripheral and central nervous system including the cortex, the cerebellum as well as 
in the midbrain and is also leading to expression in motor neurons as well  as in spinal 
cord nuclei. The onset of transgene expression is reported around postnatal day 6, 
therefore no interference with early embryonic and nervous system development is 
expected, as this could preclude any postnatal analysis. Thus hLRRK2 expression 
under the control of the murine Thy1.2 cassette should be present in areas 
responsible for movement control affected in PD patients [42, 47] and could thus 
present a suitable model for studying the role of LRRK2 in normal nervous system as 
well as in disease.  
 
The plasmid Thy1.2-LRRK2 was used for expression analysis of LRRK2 on RNA and 
protein level. RNA expression from this plasmid was detected in transfected HEK 
cells (Fig.22) but not in other cell lines. LRRK2 pr otein was only weakly detectable by 
western blot analysis, also FICC/ICC staining demonstrated LRRK2 protein 
expression albeit only in few transfected cells (Fig.24). Antibody AB9682 used for 
  81 
western blot analysis was not able to detect transgene and rec. LRRK2 protein in our 
hands. In contrast antibody NB300-268 detected LRRK2 protein in low 
concentrations but displayed high unspecific binding in Western Blotting. The 
antibody 16H7-A5 detected LRRK2 only when high amounts of protein were loaded 
but showed less unspeci fic binding in WB. 
The difficulties to detect LRRK2 protein in tissue culture using pUC18-Thy1.2 
transfected cells could be due to low transfection efficiency leading to a limited 
amount of LRRK2 expression. For this project, the transfection protocol used has 
also been changed to increase transfection efficiency by using the CaP precipitation 
method. Even though this method usually leads to high transfection efficiency in HEK 
and CHO cell s, no increase in eff iciency could be observed (data not shown) . 
Another explanation might be that inappropriate cell lines were used for in-vitro 
analysis. The mThy1.2 promoter might be only active in certain cell lines where 
glucophosphatidylinositol linked protein (Thy) is normally expressed (nervous 
system, thymus and connecti ve tissue).  
Interestingly, recent experiments performed in the lab also demonstrated that 
transfection using pCMV6-hLRRK2 as well as Thy1.2-hLRRK2 plasmids lead to 
increased cell death after 24h (C.Lahsnig, unpublished). Thus, the lack of protein 
expression and the low number of LRRK2 posi tive cells detected coul d well be based 
on a LRRK2 induced increase in apoptosis following LRRK2 expression. This would 
also be supported by recent experiments in different labs, which could show that 
mutant as well as wt LRRK2 is able to increase apoptosis, both stress dependent 
and independent, appl ying the extrinsic cell death pathway and Caspase 8 [48]. Thus 
a different assay to perform an in-depth functional analysis of LRRK2 enzyme activity 
needs to be established. One possibility would be the isolation of primary neurons 
derived from hLRRK2 transgenic animals.  
 
To start the in vivo characterization of LRRK2 function, the founder animals obtained, 
carrying the transgene, as wel l as several animals derived from breeding the di fferent 
founder animals to C57/Bl6N animals were genotyped and initially characterized. Six 
littermates (F1 generation), obtained from breeding of tg founders with C57Bl/6N wt 
animals were tested by behavioural tests, including monitoring of grooming 
behaviour, as well as the beam, pole and grid test. Due to time constraints, only 
animals with 2 and 4 months of age were included in this analysis. The animals 
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tested failed to display a significant difference between wt and tg littermates. 
However, it has to be mentioned that the number of tested animals was too small for 
a comprehensive characterization. Especially for behavioural testing, a greater 
animal number needs to be analysed in parallel to get statistically significant results 
due to big individual differences. Indeed, even though no phenotypic alterations due 
to LRRK2 over-expression have been detected in Tg animals at an age of 4 months 
but might be developing in older animals, which were not available during this 
analysis the tests have been repeated independently. Importantly, this additional 
behavioural analysis in a small cohort of animals carrying the transgene with an age 
of 8 month did show a trend for PD-like motor dysfunction (C. Lahsnig, unpublished 
information) supporting the idea that a neurodegenerative phenotype might only be 
detectable later upon aging if the animals. The fact that a PD-like phenotype is 
expected upon aging is further demonstrated by recent work of Li et al.. These 
authors could demonstrate that a hLRRK2 R1441G BAC tg mouse model developed a 
strong phenotype. The R1441G mutation used in this study is associated in humans 
with familial PD [14, 15]. At three month of age, transgenic animals did not show any 
motor deficits. In contrast at the age of 10-12 months hLRRK2 R1441G BAC tg animals 
showed defects such as immobility and impaired dopamine release. These mice 
offer, for the first time, an animal model showing cardinal features of PD. Inter estingly 
L-DOPA medication reversed this phenotype as observed in PD patients. Also 
transgenic mice over-expressing wt hLRRK2 were generated which unexpectedl y did 
not display any disease associated symptoms [41]. Similar effects of wt and mutant 
LRRK2 were found in Drosophila. Especially mutant flies showed reduced lifespan 
and increased sensi tivity to mitochondrial toxins [40].  
This observation is in accordance to our wt transgenic model where no phenotype 
was present in young animals. Nevertheless, six littermates were tested 
biochemically for LRRK2 RNA and pr otein expression.  
 
LRRK2 mRNA expression was successful ly detected in several tg animals (see 
below).  LRRK2 specific antibodies NB300-268 and 16H7-A5 were used for protein 
detection. The polyclonal NB300-268 antibody detected LRRK2 protein in lower 
concentrations than the 16H7-A5, however unspecific binding proved to be higher 
using NB300-268. Additionally, a band at the expected size of LRRK2 was also 
detected in wt and tg using both Abs. Therefore, antibodies seem to detect both 
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human and mouse LRRK2. According to results described [44] NB300-268 should be 
specific for human LRRK2 only. Interestingly, an increase in LRRK2 signal might be 
detectable in tg compared to wt animals.  
 
Detection of hLRRK2 expression by IHC on sagittal brain sections of tg and wt 
animals showed similar results as obtained by WB. Both antibodies were not able to 
discriminate between mur ine and human LRR K2. Unspeci fic binding to other  proteins 
also seems to be more pronounced with NB300-268 antibody, as shown on WB. 
16H7-A5 antibody showed weak staining of the tissue slides but a low unspecific 
binding pattern. The detection of murine and human LRRK2 however does not allow 
to clearly demonstrate hLRRK2 over-expression so far. Therefore other antibodies 
should be tested and used for transgene detection, which are able to distinguish 
between mouse and human LRRK2. Additionally, the staining protocol should be 
modified to allow hLRRK2 detect ion in situ.  
 
Currently, still many questions concerning the LRRK2 function in vivo have not been 
solved and thus there is still much research on this topic needed. Further analysis 
using this novel mouse model will be necessary to further clarify the biochemical, 
physiological and pathological function of the LRRK2 protein.  
Parkinson´s disease has a di vergent pathology with many different factors influencing 
the development of the disease. Understanding and treatment of this 
neurodegenerative disease is therefore a big topic for current neurobiological 
research. LRRK2 protein seems to play a crucial role in disease manifestation, and is 
leading to different pathologies. This property highlights the importance of evaluating 
the potential of targeting LRRK2 protein by therapeutics which might be used for 
treatment of pat ients suffering from Parkinson´s disease.  
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